


Development of (6*R*)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazine (DNDI-8219): A New Lead for Visceral LeishmaniasisAndrew M. Thompson,^{*,†} Patrick D. O'Connor,[†] Andrew J. Marshall,[†] Adrian Blaser,[†] Vanessa Yardley,[‡] Louis Maes,[§] Suman Gupta,^{||} Delphine Launay,[⊥] Stephanie Braillard,[⊥] Eric Chatelain,[⊥] Baojie Wan,[#] Scott G. Franzblau,[#] Zhenkun Ma,[@] Christopher B. Cooper,[@] and William A. Denny[†][†]Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand[‡]Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom[§]Laboratory for Microbiology, Parasitology and Hygiene, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Universiteitsplein 1, B-2610 Antwerp, Belgium^{||}Division of Parasitology, CSIR-Central Drug Research Institute, Lucknow 226031, India[⊥]Drugs for Neglected Diseases initiative, 15 Chemin Louis Dunant, 1202 Geneva, Switzerland[#]Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612, United States[@]Global Alliance for TB Drug Development, 40 Wall Street, New York, New York 10005, United States

S Supporting Information

ABSTRACT: Discovery of the potent antileishmanial effects of antitubercular 6-nitro-2,3-dihydroimidazo[2,1-*b*][1,3]-oxazoles and 7-substituted 2-nitro-5,6-dihydroimidazo[2,1-*b*][1,3]oxazines stimulated the examination of further scaffolds (e.g., 2-nitro-5,6,7,8-tetrahydroimidazo[2,1-*b*][1,3]-oxazepines), but the results for these seemed less attractive. Following the screening of a 900-compound pretomanid analogue library, several hits with more suitable potency, solubility, and microsomal stability were identified, and the superior efficacy of newly synthesized 6*R* enantiomers with phenylpyridine-based side chains was established through head-to-head assessments in a *Leishmania donovani* mouse model. Two such leads (R-84 and R-89) displayed promising activity in the more stringent *Leishmania infantum* hamster model but were unexpectedly found to be potent inhibitors of hERG. An extensive structure–activity relationship investigation pinpointed two compounds (R-6 and pyridine R-136) with better solubility and pharmacokinetic properties that also provided excellent oral efficacy in the same hamster model (>97% parasite clearance at 25 mg/kg, twice daily) and exhibited minimal hERG inhibition. Additional profiling earmarked R-6 as the favored backup development candidate.



■ INTRODUCTION

Visceral leishmaniasis (VL) is a particularly lethal sandfly-borne parasitic disease that is prevalent in more than 60 countries, where it mostly affects underprivileged people in remote rural areas who have limited access to diagnosis and treatment.^{1–3} Major outbreaks of VL in East Africa have been attributed to waves of forced migration during periods of conflict, and such epidemics are exacerbated by weak healthcare systems, malnutrition, and HIV/AIDS coinfection.^{4,5} Moreover, in this region, the first-line drug combination of paromomycin and sodium stibogluconate was found to be unsuitable for VL patients who were >50 years of age or those with HIV, and no other therapies have shown adequate efficacy.^{6,7} Failure of the

most recently evaluated new agent, fexinidazole, in a phase II clinical trial for VL in Sudan⁸ has now left the clinical pipeline empty, underlining the compelling need to develop more satisfactory medications.⁹

The target product profile (TPP) of an optimized new chemical entity for the treatment of VL requires (i) effectiveness against all causative species, in all endemic areas, in both immunocompetent and immunosuppressed individuals, with a clinical efficacy of >95%; (ii) activity against resistant strains; (iii) no adverse safety events requiring monitoring and

Received: October 24, 2017

Published: February 20, 2018



no contraindications; (iv) no drug–drug interactions (suitable for combination therapy); (v) oral administration once per day for a maximum of 10 days (or intramuscular dosing three times over 10 days); (vi) stability in relevant climates (3 years); and (vii) affordable cost (<\$80, ideally <\$10 per course).¹⁰ However, new drug discovery for VL faces formidable challenges, such as inadequate investment, a lack of validated targets, poor translation of *in vitro* activity into *in vivo* models, and meager hit rates (<0.1%) for phenotypic screening of compound libraries.^{11–13} The latter may be due in part to the concealed location of parasites in acidic parasitophorous vacuoles within macrophages.¹⁴ Furthermore, the unique glycolipid-rich cell surface of the amastigotes presents an additional barrier to chemotherapy.¹⁵ Another issue is that many cellularly active hits may never meet TPP and progression criteria, even after valiant optimization attempts.^{13,16} Nevertheless, drug development efforts spearheaded by the Drugs for Neglected Diseases initiative (DNDi) have now shown encouraging progress in several novel classes, including oxaboroles and aminopyrazoles.^{12,17,18} Novartis has also disclosed a triazolopyrimidine preclinical lead with utility *in vivo* against both leishmanial and trypanosomal infections.¹⁹

The 2-nitroimidazooxazines are best known for their potent effects against *Mycobacterium tuberculosis* (*M. tb*), the causative agent of tuberculosis (TB).²⁰ The first drug candidate from this class, pretomanid [PA-824, S-1 (Figure 1)], has shown




Figure 1. Structures of antitubercular or antileishmanial agents.

excellent safety and bactericidal efficacy in phase II clinical trials for TB,²¹ leading to its ongoing combination assessment,²² while our collaborative work with the TB Alliance on second-generation analogues of S-1 culminated in the advancement of TBA-354 (S-2) into phase I studies.²³ We have recently described the investigation of a novel 7-substituted 2-nitroimidazooxazine class, which in addition to possessing considerable potential against TB has also demonstrated exciting activity against both VL and Chagas disease, resulting in the selection of preclinical VL lead 3.²⁴ This followed an in-depth analysis of the structurally related 6-nitroimidazooxazole class,²⁵ where phenotypic screening of some of our initial examples by DNDi had enabled the discovery of previous development nominee 4 (DNDI-VL-2098).²⁶ The latter was found²⁷ to be activated by a novel leishmanial nitroreductase


(NTR2). In comparison to 4, candidate 3 exhibited an improved safety profile and had similarly notable efficacy in two animal models of VL.²⁴ Furthermore, while the new TB drug delamanid (5) has also been suggested as a possible VL therapy,²⁸ it is noteworthy that 3 was substantially more effective than this agent in the highly stringent chronic infection hamster model.^{24,25}

As part of our VL lead optimization program with DNDi, it was considered important to develop a few efficacious backup compounds having good physicochemical/pharmacological profiles and better safety, to mitigate development risks. Given the encouraging results with nitroimidazooxazines and 7-substituted 2-nitroimidazooxazines, we first evaluated various other pretomanid-related scaffolds for VL, including those with a reversed linker at C-6^{29,30} and novel nitroimidazooxazepines. We then assessed our larger collection of pretomanid analogues via the medium-throughput screening of ~900 compounds at the Institut Pasteur Korea (IPK). Finally, a more systematic synthetic approach was employed to redevelop the 6-substituted 2-nitroimidazooxazine class for VL, taking into consideration both enantiomer forms. We now report the findings from these wide-ranging structure–activity relationship (SAR) studies, including the detailed *in vitro/in vivo* profiling of selected new leads, which resulted in our identification of the title compound as a very promising VL backup candidate.

CHEMISTRY

Scheme 1 outlines the synthetic methods used to prepare eight novel racemic analogues of S-1 featuring changes to the original nitroimidazooxazine core (14, 22, 23, 32, 33, 39, 40, and 47). A common strategy (based on the original, well-validated route to S-1 and simple derivatives)^{31,32} proved to be effective for the first five of these (Scheme 1A–C), involving the initial reaction of functionalized epoxides (9,³³ 17, and 27³⁴) with 2,4-dinitroimidazole (8), followed by THP protection of the derived alcohols (10, 18, and 28). In the shorter chain cases (11 and 19), subsequent cleavage of the TBS ether (TBAF) enabled *in situ* annulation, whereas in the latter instance (29), oxazepine ring formation required additional treatment with a strong base (NaH). Removal of the THP group with methanesulfonic acid and standard alkylation chemistry on alcohols 13, 21, and 31 then gave the aforementioned targets.

For the isomeric oxazepines (Scheme 1D), THP protection of alcohol 34²⁴ and desilylation (TBAF) similarly furnished the noncyclized alcohol 36, which was ring-closed (NaH and DMF) and THP-deprotected (HCl) to produce alcohol 38. However, both final step alkylations of 38 unexpectedly cogenerated significant quantities (20–36%) of the isomeric 7-substituted oxazine derivative (41 or 42), together with the desired oxazepine ether (39 or 40). Although this is unconfirmed, it is postulated that this rearrangement may involve an intramolecular S_NAr reaction, with attack by the oxazepine alkoxide anion at the imidazole ring junction carbon 9a and subsequent alkylation of the released 2-nitroimidazooxazine 7-alkoxide (but it should be emphasized that no similar rearrangements were detected during the derivatization of 13, 21, 31, or the alcohol precursor to S-1, and that S-1 itself has shown excellent safety and a lengthy 16–18 h half-life in clinical trials for TB,³⁵ suggesting that 2-nitroimidazooxazine-based VL leads would be unlikely to demonstrate an excessive reactivity toward biological nucleophiles; this is further supported by an observed tolerance of the latter ring system toward several basic nucleophiles in the chemistry reported below). The remaining

Scheme 1^a


^aReagents and conditions: (i) 70–75 or 95 °C, 18–23 h; (ii) 3,4-dihydro-2H-pyran, PPTS, CH₂Cl₂, 20 °C, 3.5–24 h; (iii) TBAF, THF, 20 °C, 1–4.5 h, or 0–20 °C, 14 h (for 47); (iv) MsOH, MeOH, 20 °C, 1–2 h; (v) 4-OCF₃BnBr or 4-BnOBnCl or 4-BnOBnI, NaH, DMF, 20 °C for 3–20 h or 0–20 °C for 0.7–2.2 h; (vi) TBSOTf, Et₃N, CH₂Cl₂, 20 °C, 3 h; (vii) *m*-CPBA, CH₂Cl₂, 20 °C, 18 h; (viii) NaH, DMF, 20 °C for 18 h or 0–20 °C for 3.5 h; (ix) 3.3 M HCl, MeOH, 20 °C, 5 h; (x) DIPEA, toluene, 89–105 °C, 67 h.

scaffold, nitrotriazolooxazine 47, was accessed from 5-bromo-3-nitro-1,2,4-triazole (43) and iodide 44,³⁶ via desilylation/*in situ* annulation of the major adduct 46, as shown above (Scheme 1E).

The assembly of new biaryl and heterobiaryl side chain variants of S-1 and its enantiomer, R-1,^{37,38} was relatively straightforward (Schemes 2 and 3). Biphenyl analogues (R-58, R-60, and R-62) were created by Suzuki coupling reactions on halobenzyl ether derivatives of the key 6-R alcohol 56,³² while combination of 56 with bromide 63³⁹ afforded the terminal pyridine R-64 (Scheme 2A). Alternative alkylation of 56 or its 6-S equivalent 65³² with various isomeric bromomethyl bromopyridines (66, 71, 75, 82,³⁹ and 97) then set up the Suzuki-based manufacture of novel *ortho*-linked phenylpyridines [S-69, R-69, S-74, and R-74 (Scheme 2B,C)] and both *meta*- and *para*-linked congeners (Schemes 2D and 3A,C). This latter work was further expanded to include examples containing a pyridazine, pyrazine, or pyrimidine ring (R-109, R-112, and R-115), using similar chemistry³⁹ (Scheme 3D), and to a novel racemic nitrotriazole counterpart of R-84 [88 (Scheme 3B)], starting from alcohol 86.⁴⁰ Lastly, a buffered *m*-CPBA oxidation of R-84 supplied pyridine *N*-oxide R-85 (Scheme 3A).

Several reference benzyl ethers (R-1,³⁸ R-7,³² R-118, and R-119) were sourced through direct alkylations of 6-R alcohol 56³² (Scheme 4A). Three extended ether targets (R-122, R-123, and R-124) were also formed by Sonogashira reactions on

the propargyl ether R-121, derived from the coupling of 56 with bromide 120.⁴¹ Next, the orthogonally diprotected triol 125⁴² was employed in complementary syntheses of the novel R and S enantiomers of racemic ether 6⁴² (Scheme 4B,C). Following a Mitsunobu reaction of 125 with 4-(trifluoromethoxy)phenol, selective removal of the PMB group (DDQ), iodination of the resulting alcohol 127, and reaction with 2-bromo-4-nitroimidazole (129) gave silyl ether 130. Treatment of the latter with TBAF and sodium hydride-induced ring closure then produced S-6. Conversely, successive cleavage of the TIPS group from 126, iodination, and then reaction with 129 provided PMB ether 134. Oxidative debenzoylation of 134 with DDQ in the absence of water unexpectedly led to partial acetalization of the alcohol product with 4-methoxybenzaldehyde, but this mixture was cleanly converted back to 135 via acid hydrolysis (TsOH/MeOH). Base-assisted annulation of alcohol 135 (NaH) then furnished the second enantiomer, R-6. In subsequent work, 2-pyridinyl ether analogues of both R-6 (R-136, R-137, and R-138) and triazole 47 (139) were accessed from alcohols 56³² and 86,⁴⁰ respectively, via sodium hydride-catalyzed S_NAr displacement reactions on halopyridines (Scheme 4D), while Cu(I)-induced coupling of 56 with aryl isocyanates generated the O-carbamates R-140 and R-141 (Scheme 4E). Finally, piperazine carbamate R-143 was synthesized by chloroformylation of alcohol 56 and *in situ* reaction with 1-[4-(trifluoromethoxy)-phenyl]piperazine⁴³ (142) (Scheme 4F).

Scheme 2^a

^aReagents and conditions: (i) NaH, DMF, 0–20 °C, 2.3–3.5 h; (ii) ArB(OH)₂, DMF, (toluene, EtOH), 2 M Na₂CO₃ or 2 M KHCO₃, Pd(dppf)Cl₂ under N₂, 70–88 °C, 2.2–4 h; (iii) NBS, PPh₃, CH₂Cl₂, 20 °C, 3.5 h.


Further linker diversity was accessed through the transformation of 6-S alcohol **65**³² into the novel 6-R amine hydrochloride, **146** (Scheme 5A). Following tosylation of **65** and azide displacement, reduction of 6-R azide **145** with propane-1,3-dithiol gave the required amine, which was converted to its hydrochloride salt for improved stability. From this intermediate, reductive alkylation with benzaldehydes (using NaBH₃CN), acylation with benzoyl chlorides, or treatment with phenyl isocyanates in the presence of catalytic dibutyltin diacetate yielded the expected benzylamine, benzamide, or phenyl urea derivatives (Scheme 5A,B). Then, to conclude this study, a variety of shorter O-linked heterobiaryl side chains were constructed using Suzuki couplings on haloheteroaryl ether precursors [**156**, **159**, **167**, **170**, and **173** (Scheme 5C–E)]. The latter were obtained directly from alcohol **56**, via S_NAr reactions on fluoropyridines or chloropyrimidines, or, in the case of **167**, from the diprotected triol **125**⁴² and 6-bromopyridin-3-ol, using the same methodology as described above for R-6.

RESULTS AND DISCUSSION

To establish the SARs against kinetoplastid diseases, 76 new (and several known) pretomanid analogues derived from successive projects with TB Alliance and DNDi were retrospectively tested in replicate assays conducted at the University of Antwerp [LMPH (Tables 1–4)]. These assays measured activity versus the intracellular amastigote forms of both *Leishmania infantum* (*L. inf*) and *Trypanosoma cruzi* (*T.*

cruzi) and against the bloodstream form of *Trypanosoma brucei* (*T. brucei*); cytotoxicity toward human lung fibroblasts (MRC-5 cells, the host for *T. cruzi*) was also assessed.⁴⁴ Much of our VL lead optimization work with DNDi was earlier guided by the findings from single IC₅₀ determinations against *Leishmania donovani* (*L. don*) in a mouse macrophage-based luciferase assay²⁶ performed at the Central Drug Research Institute (CDRI, Pradesh, India), and by follow-up evaluations of *in vitro* microsomal stability and efficacy in the mouse VL model (Figure 2A). The best leads were then advanced to further appraisal in the more stringent hamster VL model. Overall, while excellent *in vivo* efficacy was a key goal for second-generation VL drug candidates, we also aspired (a) to minimize compound lipophilicity (estimated using ACD LogP/LogD software, version 14.04, Advanced Chemistry Development Inc., Toronto, ON) to lessen toxicity risks, (b) to increase aqueous solubility (as judged by kinetic data on dry powder forms of active leads) for optimal oral bioavailability, and (c) to reduce hERG inhibition potential (cf. 4)²⁴ to improve safety.

Scaffold Modification: Initial Hits. As part of our earlier TB studies, we had examined some fundamental changes to the nitroimidazooxazine “warhead”, including replacement of the nitroimidazole ring by nitropyrazole or nitrotriazole [e.g., **48–50** (Table 1)] and exchange of the 8-oxygen for sulfur or nitrogen.⁴⁰ We had also explored reversal of the C-6 linker (e.g., **24–26**)^{29,30} and transposition of the side chain to position 7 (e.g., **41** and **42**).²⁴ In a further extension to this work (seeking improved metabolic stability and new active

Scheme 3^a


^aReagents and conditions: (i) NaH, DMF, 0–20 °C (or 0–8 °C), 2–2.7 h; (ii) ArB(OH)₂, DMF, (toluene, EtOH), 2 M Na₂CO₃ or 2 M KHCO₃, Pd(dppf)Cl₂ under N₂, 80–89 °C for 2–4 h or 70 °C for 16 h; (iii) *m*-CPBA, Na₂HPO₄, CH₂Cl₂, 20 °C, 16 h.

scaffolds), the novel methylated derivatives **14**, **22**, and **23** were investigated, together with nitroimidazooxazepines **32**, **33**, **39**, and **40**. Unfortunately, except for the 7,7-dimethyl derivative **22** [which showed antitubercular potency comparable to that of **1** and excellent stability toward human liver microsomes, HLM, 92% after 1 h (Table 5)], these compounds proved to be unattractive for TB. Nevertheless, in preliminary antiparasitic screening at the Swiss Tropical Institute, **23**, **25**, and **26** demonstrated encouraging utility against *L. don* in a mouse macrophage assay (IC₅₀s of 1.2–1.5 μM),²⁹ and triazole **49** exhibited striking activity versus Chagas disease (*T. cruzi* IC₅₀ of 0.084 μM). For greater clarity, we will focus the discussion first on the intended main application (VL) and discuss the other parasite data in a closing section. Follow-up testing of a larger set of compounds at CDRI²⁶ identified **1**, **6**, **24**, and **40** as being superior for VL [*L. don* IC₅₀s of 0.26–0.46 μM (Table 1)], although such hits were still an order of magnitude less potent than **4** and the 7-substituted oxazine **41** (IC₅₀s of 0.03 μM).^{24,25}

These results, together with evidence of the reduced solubility and more rapid metabolism of analogues with 4-benzyloxybenzyl side chains,^{36,42} prompted the further appraisal of **24** in an *L. don* infection VL mouse model. Disappointingly, **24** displayed weak activity [31% inhibition at 25 mg/kg, dosing po daily for 5 days (Table 5)], despite its reasonable mouse PK profile [50% oral bioavailability, moderate exposure, and 2 h half-life (Table 6)]. This outcome implied the need to significantly boost *in vitro* potencies in this class. However, two highly effective phenylpyridine analogues of **24**, **116**³⁰ and **117**³⁰ [*L. don* IC₅₀s of 0.02–0.05 μM (Table 2)], also failed to

deliver useful activity in this *in vivo* assay under the same dosing regimen (23–49% inhibition). Analysis of their mouse PK data identified low oral bioavailability (11–15%) as a contributing factor here because greater oral exposure led to better efficacy [116 (Table 6 and Figure S1)]. A related concern for both compounds was poor aqueous solubility [0.13–0.27 μg/mL at pH 7 (Table 5)], while retrospective testing against *L. inf* later revealed suboptimal potency (IC₅₀s of ~6 μM). Taken together, these findings reinforced the importance of improving both potency and *in vivo* PK properties, to achieve suitable efficacy in VL models. To this end, we returned to our sizable pretomanid analogue library, where we had already amassed key solubility and DMPK information from extensive earlier studies with the TB Alliance.

Library Screening and Hit to Lead Assessments for VL. To assist the identification of more active leads from the 6-substituted nitroimidazooxazine class, an 898-member library was screened against *L. don* amastigotes in a seven-point 3-fold dilution macrophage assay at the Institut Pasteur Korea (mid-2010).⁴⁵ In total, 248 compounds (28%) showed >50% inhibition at 10 μg/mL, although only 89 (36%) of these displayed >50% inhibition at 3.3 μg/mL, and known actives from the nitroimidazooxazole and 7-substituted oxazine classes were dispersed across both groupings. By eliminating examples from previously inspected classes (including the “reversed C-6 linker” series above), we obtained a starting set of 169 hits. This set was further refined by excluding compounds with a higher propensity for metabolic and/or solubility issues, based on established trends, to give 42 hits, which were retested at CDRI.

Scheme 4^a


^aReagents and conditions: (i) NaH, DMF, 0–20 °C, 0.25–5.5 h; (ii) TBAF, THF, 20 °C, 0.5–18 h; (iii) ArI or ArBr, Et₃N, DMF, CuI, Pd(PPh₃)₂Cl₂ under N₂, 70 °C for 0.25–1 h or 20 °C for 16 h; (iv) 4-OCF₃PhOH, DEAD, PPh₃, THF, 0–20 °C, 60 h; (v) DDQ, CH₂Cl₂, 20 °C, 10–28 h (then TsOH, MeOH, 20 °C, 12 h for **135**); (vi) I₂, PPh₃, imidazole, CH₂Cl₂, 20 °C, 12–35 h; (vii) **128** or **133**, K₂CO₃, DMF, 85–92 °C, 64–111 h; (viii) CuCl, DMF, 20 °C, 33–43 h; (ix) triphosgene, Et₃N, THF, 0–20 °C, 1.7 h, then **142**, THF, 20 °C, 3.5 h.

The most relevant results are summarized in Figure 3, with almost all of the remaining hits manifesting weaker potencies (*L. don* IC₅₀s of 0.5–11 μM). We also screened **S-1** and **S-2**, but both had only modest activities (*L. don* IC₅₀s of 3.9 and 2.6 μM, respectively). Nevertheless, in view of the 10-fold higher potency of racemic **1** [IC₅₀ of 0.39 μM (Table 1)], this result for **S-1** was highly significant as it implied that 6R enantiomers (which have little activity against *M. tb*^{32,37}) may be the more active chiral form for VL. Therefore, we synthesized a trial set of 10 compounds (**R-1**, **R-2**, **R-7**, **R-58**, **R-60**, **R-62**, **R-77**, **R-81**, **R-84**, and **R-94**) for assessment. In 9 of 10 cases, these 6R enantiomers exhibited 1.1–12-fold superior potencies [*L. don* IC₅₀s of 0.06–1.4 μM (see Tables S2 and S3)]; hence, the 6R counterparts of selected hits in Figure 3 were also targeted (in line with the approach in Figure 2A).

In an effort to further prioritize the library screening hits for *in vivo* evaluation, five compounds of high lipophilicity (CLogP > 4 for **S-53**,⁴⁶ **S-54**,³⁰ **S-55**,⁴⁷ **S-58**,⁴⁷ and **S-64**³⁹) were omitted from further study and the remaining 12 were assessed for aqueous solubility and microsomal stability (Table 5 and cited references for Figure 3). Both the amide **S-151**⁴⁸ and urea **S-155** provided encouraging solubility data (132 and 22 μg/mL, respectively), but the urea unexpectedly showed poor stability toward mouse liver microsomes (MLM, 43% parent after 30

min). Conversely, both the lipophilic arylthiazole **S-51**⁴⁹ (CLogP ~ 4.0) and the arylpyrimidine **S-171**⁴² were considered of borderline interest because of their modest solubility values (0.9–1.6 μg/mL). While some phenylpyridine hits (e.g., **S-77**, **S-89**, **S-91**, **S-92**, and **S-99**)³⁹ were not substantially more soluble than this at pH 7 (1.4–4.0 μg/mL), these compounds have demonstrated greatly superior results at pH 1 (211–1780 μg/mL). It has been recognized that the low pH of gastric fluid (typically ~1–2) can enhance the dissolution and oral absorption of such weak bases.⁵⁰ Furthermore, close analogue **S-2** was advanced to clinical studies for TB partly on the basis of its superior *in vivo* PK properties in comparison to those of delamanid (**5**), which are absorption-limited.²³ Concordant with this, the most potent phenylpyridine hits in Figure 3 (**S-77**, **S-81**, **S-89**, **S-91**, and **S-92**) also displayed broadly acceptable HLM and MLM stabilities (>70% remaining after 30 min), suggesting their suitability for *in vivo* studies.

The best six screening hits mentioned above (phenylpyridines **S-77**, **S-81**, **S-89**, **S-91**, and **S-92** and amide **S-151**) were then evaluated in the mouse VL model alongside a similar set of 6R enantiomers (**R-77**, **R-84**, **R-89**, **R-91**, **R-92**, **R-94**, and **R-151**), dosing at 50 mg/kg orally, once daily for 5 days. Results for the *meta*-linked phenylpyridines **R-77**, **S-77**, and **S-81** were not particularly impressive [52, 44, and 35% inhibition,

Scheme 5^a


^aReagents and conditions: (i) TsCl, pyridine, 49 °C, 17 h; (ii) NaN₃, DMSO, 64 °C, 3.5 days; (iii) HS(CH₂)₃SH, Et₃N, MeOH, 20 °C, 0.5 h, then HCl, dioxane; (iv) NaBH₃CN, AcOH, DMF, 0–20 °C, 7–20 h; (v) DIPEA, DMF, 20 °C, 10–25 h; (vi) NMM or DIPEA, Bu₃Sn(OAc)₂, DMF, 20 °C, 4–18 h; (vii) NaH, DMF, 0–20 °C, 2.7–3.4 h; (viii) ArB(OH)₂, DMF, toluene, EtOH, 2 M Na₂CO₃, Pd(dppf)Cl₂ under N₂, 84–89 °C, 1.3–3.5 h; (ix) 6-bromopyridin-3-ol, DEAD, PPh₃, THF, 0–20 °C, 89 h; (x) TBAF, THF, 20 °C, 13 h; (xi) I₂, PPh₃, imidazole, CH₂Cl₂, 20 °C, 41 h; (xii) 164, K₂CO₃, DMF, 88 °C, 122 h; (xiii) DDQ, CH₂Cl₂, 20 °C, 98 h, then TsOH, MeOH, CH₂Cl₂, 20 °C, 10 h.

respectively (Table 5)], although the level of activity did track with their respective *L. don* IC₅₀s (0.06, 0.12, and 0.24 μM, respectively). In contrast, pairwise comparison of *para*-linked phenylpyridines S-89, S-91, and S-92 with their 6R counterparts unequivocally confirmed the latter as being superior [R-89 (99.5%) vs S-89 (45%), R-91 (99.8%) vs S-91 (69%), and R-92 (94%) vs S-92 (37%)], notwithstanding their slightly higher rates of metabolism (e.g., R-91, 81% parent after 30 min in MLM, vs S-91, 100%). In this series, the 4-fluoro analogue R-94 (*L. don* IC₅₀ of 0.18 μM) showed reduced utility (83%), whereas the apparently less potent 4-trifluoromethoxy congener R-84 (IC₅₀ of 0.32 μM in the same CDRI assay) provided excellent efficacy (99.4%), despite having lower microsomal stability (36% vs 66% after 1 h in MLM). Overall, the most effective (6S) screening hit was the soluble amide S-151 (72%), but its 6R form (R-151) was unexpectedly poor (5%). However, for this 6-N-linked benzamide class, it was later discovered that the 6S enantiomers had the stronger *in vitro* potencies (e.g., *L. inf* IC₅₀s of 5.6 and 12 μM for S-151 and R-151, respectively), suggesting the need for a more systematic investigation of the SAR (Figure 2B). For better clarity, we will describe this analysis next, before summarizing the results from additional *in vivo* assessments on all of the most active new VL leads.

SAR of 6-Substituted 2-Nitroimidazooxazines for VL

Following the discovery that many 6R enantiomers had superior *in vitro* and *in vivo* activities against VL, a more extensive lead optimization study was initiated to develop additional backup candidates to 4 possessing an advantageous solubility, PK–PD, and safety profile. In light of the high potency of *ortho*-linked biphenyl hit S-58 (*L. don* IC₅₀ 0.18 μM), we first sought to establish the optimal linking position for biaryl side chains. Comparison of R-58, R-60, and R-62 in both *L. don* and *L. inf* assays (Table 2) unexpectedly indicated that *ortho* linkage was most preferred and that *para* linkage was least preferred. Therefore, the novel *ortho*-linked phenylpyridines S-69, R-69, S-74, and R-74 were studied. Here, R-69 and R-74 were equally best, although 1.8-fold less effective than R-58 (*L. inf* IC₅₀s of 2.0 vs 1.1 μM). Interestingly, these two phenylpyridine isomers showed major differences in both solubility and microsomal stability, with the more soluble R-74 (78 vs 0.51 μg/mL) being metabolized extremely rapidly in all three microsome species [0.1–8% remaining after 1 h (Table 5)], whereas R-69 was more stable than the *para*-linked analogue R-84 described above (44% vs 36% after 1 h in MLM).

In the *meta*-linked phenylpyridine series, two new compounds (R-79 and R-80) having terminal ring substituents

Table 1. *In Vitro* Antiparasitic and Antitubercular Activities for Racemic Nitroheterobicyclic Scaffold Variants


Chemical structures A-I are shown above the table. A box defines Y as either a 4-substituted phenyl group (a) or a 4-substituted benzyl group (b), where R is a substituent.


compd	form	R	CLogP	IC ₅₀ ^{a,b} (μM)				MRC-5	MIC ^{b,c} (μM)	
				<i>L. don</i>	<i>L. inf</i>	<i>T. cruzi</i>	<i>T. brucei</i>		MABA	LORA
6 ^d	Aa	OCF ₃	2.48	0.39	0.95	0.39	>64	>64	2.9	9.6
1 ^e	Ab	OCF ₃	2.70	0.39	4.0	1.2	>64	>64	1.1	4.4
7 ^e	Ab	OBn	3.32	1.1	5.9	0.38	>64	>64	0.11	2.7
14	Bb	OCF ₃	3.24	78	>64	50	>64	>64	7.4	55
22	Cb	OCF ₃	3.74	5.5	2.2	0.53	34	>64	1.2	9.6
23	Cb	OBn	4.36	0.77	2.5	0.27	29	>64	2.2	8.3
24 ^f	Da	OCF ₃	2.78	0.46	4.0	<0.13	>64	>64	0.63	16
25 ^f	Db	OCF ₃	2.77	2.6	1.7	<0.13	>64	>64	2.4	7.9
26 ^f	Db	OBn	3.39	2.0	2.6	<0.13	>64	>64	3.1	35
32	Eb	OCF ₃	2.74	>2	>64	51	>64	>64	>128	>128
33	Eb	OBn	3.36	>2	16	2.3	23	>64	>128	>128
39	Fb	OCF ₃	2.74	0.63	>64	4.2	>64	58	52	35
40	Fb	OBn	3.36	0.26	>64	2.3	3.2	>64	>128	86
41 ^g	Gb	OCF ₃	2.88	0.03	0.12	1.2	>64	>64	1.0	7.5
42 ^g	Gb	OBn	3.50	0.05					0.46	3.0
47	Ha	OCF ₃	2.51		>64	1.3	>64	>64		
48 ^e	Hb	OCF ₃	2.74		>64	0.73	38	>64	>128	>128
49 ^e	Hb	OBn	3.36		>64	0.25	>64	>64	>128	>128
50 ^e	Ib	OCF ₃	3.26		>64	8.2	46	>64	>128	>128

^aIC₅₀ values for inhibition of the growth of *L. don* and *L. inf* (in mouse macrophages), *T. cruzi* (on MRC-5 cells), and *T. brucei*, or for cytotoxicity toward human lung fibroblasts (MRC-5 cells). ^bEach value (except the single-test *L. don* data) is the mean of at least two independent determinations. For complete results (mean ± SD), see the Supporting Information. ^cMinimum inhibitory concentration against *M. tb*, determined under aerobic (MABA)⁵⁹ or hypoxic (LORA)⁶⁰ conditions. ^dTB data from ref 42. ^eTB data from ref 40. ^fTB data from ref 30. ^gData from ref 24.

favorable in *para*-linked isomers described above (2-F, 4-OCF₃, and 4-OCF₂H) were marginally more potent than *R*-77 (4-OCF₃) and *R*-81 (4-F) [*L. inf* IC₅₀s of 0.45 and 0.51 vs 0.63 and 0.73 μM, respectively (Table 2)]. Here, replacement of the proximal phenyl ring in *R*-60 by 2-pyridine (*R*-77) resulted in a 3.7-fold improvement in activity (*L. inf* IC₅₀s of 2.3 and 0.63 μM). This enhancement by 2-pyridine was even more pronounced in the *para*-linked phenylpyridine series (*L. inf* IC₅₀s of 0.71 and >64 μM for *R*-84 and *R*-62, respectively), clarifying that with this heterocycle, *ortho* linkage was less useful than *meta* or *para* linkage. However, in the *para*-linked set, we considered that the 2'-nitrogen would have less steric protection against oxidation, perhaps accounting for the modest microsomal stabilities of some analogues. Indeed, we could form the *N*-oxide derivative of *R*-84 (*R*-85), which was found to be 2.3-fold less potent (*L. inf* IC₅₀ of 1.6 μM). Because microsomal stability varied significantly with the substituents in the terminal ring, we evaluated three new congeners (*R*-90, 3-F, 4-OCF₃; *R*-93, 4-CF₃; *R*-96, 2,4-diF). The most promising of these was *R*-96 (*L. inf* IC₅₀ of 1.2 μM, activity ~2-fold weaker than those of early leads *R*-84, *R*-89, *R*-91, and *R*-92), which exhibited a better stability profile in MLM and HLM [57–59% vs 16–40% for *R*-84, *R*-89, and *R*-91 (Table 5)].

As suggested by the screening data (Figure 3), replacement of the proximal phenyl ring in *R*-62 with 3-pyridine (*R*-2) was less favorable [*L. inf* IC₅₀ of 4.1 μM vs 0.71 μM for *R*-84 (Table 2)]. Nevertheless, the 6*R* enantiomers of two hits (*R*-99, 2-F, 4-OCF₃; *R*-101, 2-Cl, 4-OCF₃) and the novel 2,4-difluoro analogue *R*-106 all displayed good potencies (*L. inf* IC₅₀s of 1.1, 0.61, and 0.85 μM, respectively) and microsomal stabilities at least comparable to those of their 2-pyridine counterparts, although *R*-101 was cytotoxic (MRC-5 IC₅₀ of 17 μM). By extension, we examined three less lipophilic diaza proximal rings (*R*-109, *R*-112, and *R*-115) that had proven to be very effective in our TB studies,³⁹ but these turned out to be of less interest (*L. inf* IC₅₀s of 1.4–2.8 μM). In summary, several new phenylpyridines provided profiles that were attractive for *in vivo* evaluation, but we had yet to investigate other linker groups. Therefore, we next turned our attention to simpler monoaryl side chains to explore these changes. For this part of the study, we restricted our focus to linkers that had shown particular promise either in the initial screening (e.g., 6-O, 6-NHCO, and 6-NHCONH) or in our earlier TB work.

Commencing with the enantiomer of pretomanid [*R*-1, *L. inf* IC₅₀ of 4.7 μM (Table 3)], we found variation of the trifluoromethoxy position identified that *ortho* substitution was

Table 2. *In Vitro* Antiparasitic Activities of 6-OCH₂/CH₂O-Linked Biaryl Nitroimidazooxazines


compd	form	link	aza	R	CLogP	IC ₅₀ ^{a,b} (μM)				
						<i>L. don</i>	<i>L. inf</i>	<i>T. cruzi</i>	<i>T. brucei</i>	MRC-5
S-51 ^c					3.97	0.25	2.3	4.2	>64	>64
S-52 ^c					2.60	0.40	5.2	4.9	>64	>64
S-58 ^d	A	2'		4-OCF ₃	4.36	0.18	30	0.88	>64	>64
R-58	B	2'		4-OCF ₃	4.36	0.17	1.1	0.64	>64	>64
R-60	B	3'		4-OCF ₃	4.36	0.31	2.3	0.43	22	62
R-62	B	4'		4-OCF ₃	4.36	1.2	>64	0.12	>64	>64
S-64 ^e	A	4'	2	4-CF ₃ , 6-Cl	4.46	0.13	1.5	3.3	54	>64
R-64	B	4'	2	4-CF ₃ , 6-Cl	4.46	0.21	0.87	0.65	43	57
S-69	A	2'	3'	4-OCF ₃	3.01	28	>64	6.7	>64	>64
R-69	B	2'	3'	4-OCF ₃	3.01	0.78	2.0	1.9	>64	>64
S-74	A	2'	6'	4-OCF ₃	3.04	4.8	9.1	6.3	>64	>64
R-74	B	2'	6'	4-OCF ₃	3.04	0.86	2.0	1.3	18	>64
S-77 ^e	A	3'	2'	4-OCF ₃	3.01	0.12	1.9	2.0	>64	47
R-77	B	3'	2'	4-OCF ₃	3.01	0.06	0.63	0.25	46	61
S-79	A	3'	2'	2-F, 4-OCF ₃	3.57		2.4	3.8	>64	>64
R-79	B	3'	2'	2-F, 4-OCF ₃	3.57		0.45	0.56	>64	>64
R-80	B	3'	2'	4-OCF ₂ H	2.16		0.51	0.26	>64	>64
S-81 ^e	A	3'	2'	4-F	2.10	0.24	32	3.9	>64	>64
R-81	B	3'	2'	4-F	2.10	0.12	0.73	0.36	>64	>64
S-84 ^e	A	4'	2'	4-OCF ₃	3.04	0.83	10	1.4	43	>64
R-84	B	4'	2'	4-OCF ₃	3.04	(0.24) ^f	0.71	0.043	>64	>64
S-85 ^g	A	4'	2'-O ^h	4-OCF ₃	0.94		9.1	5.4	11	>64
R-85	B	4'	2'-O ^h	4-OCF ₃	0.94		1.6	3.3	>64	>64
88 ⁱ					3.08		41	0.52	3.5	14
S-89 ^e	A	4'	2'	2-F, 4-OCF ₃	3.60	0.18	14	1.8	>64	>64
R-89	B	4'	2'	2-F, 4-OCF ₃	3.60	(0.27) ^f	0.62	0.078	>64	>64
R-90	B	4'	2'	3-F, 4-OCF ₃	3.02		3.5	0.025	>64	>64
S-91 ^e	A	4'	2'	2-Cl, 4-OCF ₃	3.75	0.16	2.4	2.5	35	20
R-91	B	4'	2'	2-Cl, 4-OCF ₃	3.75	(0.31) ^f	0.57	0.12	35	41
S-92 ^e	A	4'	2'	4-OCF ₂ H	2.19	0.08	3.4	1.2	46	>64
R-92	B	4'	2'	4-OCF ₂ H	2.19	0.86	0.63	0.078	>64	>64
R-93	B	4'	2'	4-CF ₃	3.17		6.1	0.072	>64	>64
R-94	B	4'	2'	4-F	2.13	0.18	2.3	0.16	>64	>64
S-96	A	4'	2'	2,4-diF	2.67		1.4	7.8	>64	>64
R-96	B	4'	2'	2,4-diF	2.67	(0.39) ^f	1.2	0.23	55	>64
R-2	B	4'	3'	4-OCF ₃	3.01	1.4	4.1	0.27	>64	>64
S-99 ^e	A	4'	3'	2-F, 4-OCF ₃	3.57	0.33	>64	1.4	>64	>64
R-99	B	4'	3'	2-F, 4-OCF ₃	3.57	(0.48) ^f	1.1	0.19	>64	>64
R-100	B	4'	3'	3-F, 4-OCF ₃	2.99		12	0.24	>64	>64
S-101 ^e	A	4'	3'	2-Cl, 4-OCF ₃	3.72	0.34	5.2	2.4	23	20
R-101	B	4'	3'	2-Cl, 4-OCF ₃	3.72		0.61	0.15	34	17
R-102	B	4'	3'	4-OCF ₂ H	2.16		1.9	0.56	>64	>64
R-103	B	4'	3'	4-CF ₃	3.14		11	0.64	>64	>64
R-104	B	4'	3'	4-F	2.10		1.9	1.7	>64	>64
S-106	A	4'	3'	2,4-diF	2.64		5.3	51	>64	>64
R-106	B	4'	3'	2,4-diF	2.64	(0.64) ^f	0.85	1.3	>64	>64
R-109	B	4'	2',3'	4-OCF ₃	1.52		2.3	0.55	>64	>64
R-112	B	4'	2',5'	4-OCF ₃	2.19		2.8	0.27	>64	>64
R-115	B	4'	2',6'	4-OCF ₃	2.63		1.4	0.28	>64	>64
116 ^g	C	4'	3'	4-OCF ₃	3.38	0.05	6.1	<0.13	0.63	>64
117 ^g	C	4'	3'	4-F	2.46	0.02	6.3	<0.13	17	>64

^aIC₅₀ values for inhibition of the growth of *L. don* and *L. inf* (in mouse macrophages), *T. cruzi* (on MRC-5 cells), and *T. brucei*, or for cytotoxicity toward human lung fibroblasts (MRC-5 cells). ^bEach value (except the single-test *L. don* data) is the mean of at least two independent

Table 2. continued

determinations. For complete results (mean $\pm$ SD), see the [Supporting Information](#). ^cFrom ref 49. ^dFrom ref 47. ^eFrom ref 39. ^fLMPH data (mean of three or four values). ^gFrom ref 30. ^hN-Oxide. ⁱRacemic nitrotriazolooxazine analogue of R-84.

Table 3. *In Vitro* Antiparasitic Activities of Various Linked Monoaryl Nitroimidazooxazines


A: Z=CH; C: Z=N B: Z=CH; D: Z=N

compd	form	X	aza	R	CLogP	IC ₅₀ ^{a,b} (μM)				
						<i>L. don</i>	<i>L. inf</i>	<i>T. cruzi</i>	<i>T. brucei</i>	MRC-5
S-1 ^c	A	OCH ₂		4-OCF ₃	2.70	3.9	59	10	>64	>64
R-1 ^d	B	OCH ₂		4-OCF ₃	2.70	0.54	4.7	0.40	>64	>64
R-118	B	OCH ₂		3-OCF ₃	2.70		2.5	0.31	>64	>64
R-119	B	OCH ₂		2-OCF ₃	2.70		1.4	0.20	>64	>64
S-48 ^e	C	OCH ₂		4-OCF ₃	2.74		>64	0.74	>64	>64
R-48 ^e	D	OCH ₂		4-OCF ₃	2.74		>64	0.54	>64	>64
S-7 ^c	A	OCH ₂		4-OBn	3.32	1.7	>64	51	>64	>64
R-7 ^c	B	OCH ₂		4-OBn	3.32	0.14	0.87	0.39	>64	>64
R-122	B	OCH ₂ C≡C		4-OCF ₃	3.94		0.33	0.11	>64	>64
R-123	B	OCH ₂ C≡C	2	4-CF ₃	2.47		0.44	1.4	21	28
R-124	B	OCH ₂ C≡C	3	4-CF ₃	2.47		0.53	1.2	>64	>64
S-6	A	O		4-OCF ₃	2.48		8.2	7.3	>64	>64
R-6	B	O		4-OCF ₃	2.48	(0.19) ^f	0.53	0.15	>64	>64
R-136	B	O	2	4-CF ₃	2.33	(0.15) ^f	1.1	0.34	25	>64
R-137	B	O	2	3-CF ₃	2.13		1.2	0.35	>64	>64
R-138	B	O	2	5-CF ₃	1.73		0.85	2.4	23	>64
139 ^g					2.37		>64	23	>64	>64
R-24 ^h	A	CH ₂ O		4-OCF ₃	2.78	0.13	0.86	0.33	57	>64
S-24 ^h	B	CH ₂ O		4-OCF ₃	2.78	0.11	2.2	<0.13	>64	>64
S-140 ^c	A	CONH		4-OCF ₃	2.11	3.3	7.3	6.8	>64	>64
R-140	B	CONH		4-OCF ₃	2.11		2.1	3.5	48	>64
R-141	B	CONH		2-OCF ₃	2.51		6.4	1.5	>64	>64
S-143 ⁱ	A	OCOpip ^j		4-OCF ₃	1.56	0.88	14	2.1	>64	>64
R-143	B	OCOpip ^j		4-OCF ₃	1.56		17	0.27	>64	>64
S-147 ⁱ	A	NHCH ₂		4-OCF ₃	2.26	6.1	>64	11	3.6	>64
R-147	B	NHCH ₂		4-OCF ₃	2.26		12	1.8	3.3	>64
R-148	B	NHCH ₂		3-OCF ₃	2.26		6.9	<0.13	2.0	>64
R-149	B	NHCH ₂		2-OCF ₃	2.26		8.6	0.15	2.1	>64
S-150 ^c	A	NHCO		4-OCF ₃	1.75		6.0	19	>64	>64
R-150	B	NHCO		4-OCF ₃	1.75		57	2.5	>64	>64
S-151 ⁱ	A	NHCO		3-OCF ₃	1.22	0.25	5.6	25	>64	>64
R-151	B	NHCO		3-OCF ₃	1.22		12	0.87	>64	>64
S-152 ⁱ	A	NHCO		2-OCF ₃	1.40		5.8	53	>64	>64
R-152	B	NHCO		2-OCF ₃	1.40		18	0.96	>64	>64
S-154 ^c	A	NHCONH		4-OCF ₃	1.47		10	7.5	22	>64
R-154	B	NHCONH		4-OCF ₃	1.47		>64	2.3	19	>64
S-155	A	NHCONH		2-OCF ₃	1.73	0.23	6.8	3.1	4.9	16
R-155	B	NHCONH		2-OCF ₃	1.73		55	1.3	>64	48

^aIC₅₀ values for inhibition of the growth of *L. don* and *L. inf* (in mouse macrophages), *T. cruzi* (on MRC-5 cells), and *T. brucei*, or for cytotoxicity toward human lung fibroblasts (MRC-5 cells). ^bEach value (except the single-test *L. don* data) is the mean of at least two independent determinations. For complete results (mean $\pm$ SD), see the [Supporting Information](#). ^cFrom ref 32. ^dFrom ref 38. ^eFrom ref 40. ^fLMPH data (mean of three values). ^gRacemic nitrotriazolooxazine analogue of R-136. ^hFrom ref 30. ⁱFrom ref 48. ^jN-Piperazine.

best (R-119, *L. inf* IC₅₀ of 1.4 μM), followed by *meta* substitution (R-118), mimicking findings for biphenyl linkage. Switching to a propargyl ether⁴² (R-122) produced much greater activity (*L. inf* IC₅₀ of 0.33 μM), which was largely retained in trifluoromethylpyridine replacements for the aryl ring²⁵ (*L. inf* IC₅₀s of 0.44 and 0.53 μM for R-123 and R-124, respectively). Conversely, removal of the benzylic methylene

(R-6) also enabled high potency (*L. inf* IC₅₀ of 0.53 μM, *L. don* IC₅₀ of 0.19 μM), while critically allowing the retention of good aqueous solubility (12 μg/mL) and high microsomal stability [79–81% parent after 1 h in MLM and HLM (Table 5)]. Therefore, we similarly investigated trifluoromethylpyridine analogues of R-6 (R-136, R-137, and R-138) and while there was an ~2-fold loss of activity, R-136 demonstrated a 9-fold

Table 4. *In Vitro* Antiparasitic Activities of 6-O-Linked Biaryl Nitroimidazooxazines


compd	form	link	aza	R	CLogP	IC ₅₀ ^{a,b} (μM)				
						<i>L. don</i>	<i>L. inf</i>	<i>T. cruzi</i>	<i>T. brucei</i>	MRC-5
R-157	B	3'	2'	4-OCF ₃	3.27		0.31	<0.13	7.5	>64
R-158	B	3'	2'	4-F	2.35		0.41	0.30	>64	>64
R-160	B	4'	2'	4-OCF ₃	3.35		0.64	0.11	9.3	42
R-161	B	4'	2'	4-F	2.43		0.43	<0.13	10	>64
R-168	B	4'	3'	4-OCF ₃	3.07		0.13	0.15	>64	>64
R-169	B	4'	3'	4-F	2.15		0.20	0.40	>64	>64
S-171 ^c	A	3'	4',6'	4-OCF ₃	2.79	0.10	23	2.0	>64	47
R-171	B	3'	4',6'	4-OCF ₃	2.79		21	<0.13	>64	>64
R-172	B	3'	4',6'	4-F	1.87		49	0.68	>64	>64
R-174	B	4'	2',6'	4-OCF ₃	2.71		0.65	0.48	>64	>64
R-175	B	4'	2',6'	4-F	1.80		0.83	0.64	>64	>64

^aIC₅₀ values for inhibition of the growth of *L. don* and *L. inf* (in mouse macrophages), *T. cruzi* (on MRC-5 cells), and *T. brucei*, or for cytotoxicity toward human lung fibroblasts (MRC-5 cells). ^bEach value (except the single-test *L. don* data) is the mean of at least two independent determinations. For complete results (mean ± SD), see the Supporting Information. ^cFrom ref 42.




Figure 2. Schematic diagram of the two lead optimization approaches (A and B) employed.

improvement in aqueous solubility (110 μg/mL), together with a slower rate of metabolism (90–92% parent after 1 h in MLM and HLM). However, changing to an O-carbamate linker⁴⁸ (R-140, R-141, and R-143) proved to be less satisfactory, with moderate to low potencies observed (*L. inf* IC₅₀s of 2.1–17 μM).

Another option to improve solubility was to replace the ether linkage at C-6 with nitrogen-based linkers.⁴⁸ The 6-amino analogue of R-1 (R-147) had a 5-fold better solubility value at pH 7 (84 μg/mL) and was >2000 times more soluble at pH 1. Nevertheless, this compound was less stable toward microsomes (e.g., 61% vs 86% in MLM) and showed 2.6-fold lower activity (*L. inf* IC₅₀ of 12 vs 4.7 μM), which was not sufficiently improved by varying the ring substituent position (R-148 and R-149). Alternatively, with a carboxamide or urea linker, the enantiomer preference was reversed, with the original 6S forms (S-150, S-151, S-152, S-154, and S-155) being clearly superior but not particularly potent (*L. inf* IC₅₀s of ~6–10 μM). Hence, the only compounds with useful antileishmanial activity were ether-linked at C-6, although it was apparent that the original OCH₂ linkage was not optimal and that removal of the benzylic methylene may have metabolic stability and potency advantages. To investigate this further, a small set of O-linked phenylpyridine and phenylpyrimidine derivatives was evaluated

(Table 4). In the phenylpyridine series (R-157 to R-169), activity against *L. inf* was similar to or better than that for R-6, with the 3-pyridine isomers preferred (R-168 and R-169, IC₅₀s of 0.13–0.20 μM). These latter compounds exhibited microsomal stabilities comparable to those of the parent linker series above, but their solubility values were inferior (0.36–1.2 μg/mL at pH 7). Finally, contrary to the screening data for S-171, a proximal pyrimidine ring was tolerated only when it was *para*-linked (R-174 and R-175, *L. inf* IC₅₀s of 0.65–0.83 μM). Generally, potency against *L. inf* was more discriminating and tended to better correlate with *in vivo* outcomes.^{24,25}

Throughout the course of these studies, 10 more candidates (R-1, R-6, R-69, R-96, R-99, R-106, R-136, R-147, R-168, and R-169) were screened for activity in the mouse VL model at 50 mg/kg [dosing po daily for 5 d (Table 5)]. The *ortho*-linked phenylpyridine R-69 was disappointing (20% inhibition), but the new *para*-linked analogues R-96, R-99, and R-106 displayed high efficacies (91–97%). More heartening still was the fact that shorter chain phenylpyridines R-168 and R-169 gave essentially complete clearance of the parasite infection (99.9%), as did their monoaryl counterparts, R-6 and R-136. However, both R-1 and its amino-linked equivalent R-147 were unsatisfactory (50 and 12%, respectively), consistent with their weaker *in vitro* potencies. During the concluding stages of this project, Patterson et al.³⁸ reported that R-1 was a potential oral treatment for VL on the basis of its *in vivo* activity in a comparable mouse model at a much larger dose of 100 mg/kg *twice daily*, but it is clear from these results and other studies²⁴ that R-1 may not be the optimal development candidate.

Additional Assessments To Determine the Best VL Lead. Dose–response experiments on 7 of the 10 best compounds (R-6, R-84, R-89, R-91, R-92, R-96, and R-99) in the mouse VL model yielded ED₅₀ values of 7.5, 12, 14, 28, 20, 28, and 19 mg/kg, respectively (Table 5 and Figure 4). The more recent O-linked leads, R-136, R-168, and R-169, were also evaluated at a smaller dose of 6.25 mg/kg and provided parasite burden reductions of 30, 99.7, and 72%, respectively. The most efficacious of these (R-168) produced 84% inhibition at 3.13 mg/kg, representing activity at a level similar to that of

Table 5. Aqueous Solubility, Microsomal Stability, and *in Vivo* (mouse) Antileishmanial Efficacy Data for Selected Analogues

compd	aqueous solubility ^a ($\mu\text{g/mL}$)		microsomal stability ^b [% remaining at 1 (0.5) h]			<i>in vivo</i> efficacy against <i>L. don</i> (% inhibition at dose in mg/kg) ^c				
	pH 7	pH 1	H	M	Ham	50	25	12.5	6.25	ED ₅₀ ^d
S-1	19		82	94						
R-1	18		92	86	31	50				
R-6	12		81	79	19	>99	>99	81	42	7.5
22	6.0		92	72						
24	3.9		(78)	(88)	(70)		31			
S-51	1.6		(78)	(75)	(43)					
S-52	2.7		87	67						
R-69	0.51	263	35	44	3.0	20				
R-74	78	7350	8.0	0.2	0.1					
S-77	3.0	211	(75)	(78)	(31)	44				
R-77	1.5	167	(68)	(68)	(31)	52				
S-81	15	439	(96)	(74)	(15)	35				
R-81	6.0	691	(79)	(68)	(0)					
R-84	3.0	1040	27 (66)	36 (70)	10 (61)	>99	76	42	36	12
S-89	1.4	479	(88)	(84)	(69)	45				
R-89	3.4	503	27 (75)	40 (79)	10 (69)	>99	72	48	17	14
S-91	1.4	384	(73)	(100)	(75)	69				
R-91	2.9	12	16 (65)	27 (81)	5.8 (57)	>99	38	6		28
S-92	4.0	1780	(92)	(88)	(59)	37				
R-92	5.7	2050	49 (71)	56 (86)	11 (45)	94	54	20		20
R-94	11	4600	58 (85)	66 (77)	10 (37)	83				
R-96	40	7140	59	57	5.2	97	48	29	17	28
R-99	2.9	364	37	41	9.2	97	64	31	8	19
R-102	2.1	857	58	56	7.9					
R-106	3.9	925	58	67	10	91				
116	0.13	32	(88)	(96)	(88)		49			
117	0.27	132	(85)	(66)	(64)		23			
R-136	110		90	92	48	>99			30	
R-147	84	38100	84	61	7.5	12				
S-151	132		(100)	(83)	(81)	72				
R-151	85		87	86	59	5				
S-155	22		(74)	(43)	(64)					
R-168	0.36	36	40	35		>99			>99	<3.1
R-169	1.2	325	73	59		>99			72	

^aKinetic solubility in water (pH 7) or 0.1 M HCl (pH 1) at 20 °C, determined by HPLC (see Method A in Experimental Section). ^bPooled human (H), CD-1 mouse (M), or hamster (Ham) liver microsomes; data in parentheses are the percentage parent compound remaining following a 30 min incubation. ^cDosing was done orally, once daily for 5 days consecutively; data are the mean percentage reduction of parasite burden in the liver. ^dDose in milligrams per kilogram required to achieve a mean 50% reduction in parasite burden.

the nitroimidazooxazole **4**,^{25,26} albeit marginal aqueous solubility (0.85 μM at pH 7) deterred its advanced assessment. Instead, we elected to focus initially on the monoaryl ethers **R-6** and **R-136**, together with phenylpyridines **R-84** and **R-89**, which all produced favorable mouse PK data, including excellent oral exposure levels and half-lives of 6–30 h (Table 6 and Figure S1).

The selected candidates were further assessed in the chronic infection hamster model, which is considered the bona fide experimental model for VL because it mimics many features of progressive human disease.⁵¹ Pleasingly, at 50 mg/kg twice daily for 5 days, phenylpyridine **R-84** achieved 99.9–100% *L. inf* clearance in all three target organs, and **R-89** was almost as good (Table 7 and Figure 5), although both compounds were less inhibitory in bone marrow at 25 mg/kg b.i.d. (81–88%). The monoaryl ethers **R-6** and **R-136** were even more effective at both dose levels, enabling a 97–99% parasite kill at 25 mg/kg b.i.d. (for comparison, this efficacy level was similar to that observed for **3** at 12.5 mg/kg b.i.d.²⁴). Pyridinyl ether **R-136** additionally demonstrated fully curative activity (100% parasite

clearance in all three organs) at 25 mg/kg b.i.d. in an *L. don* infection hamster model. Three more phenylpyridines (**R-96**, **R-99**, and **R-106**) were similarly evaluated in the *L. inf* hamster model, but only **R-99** (the 3-pyridyl isomer of **R-89**) showed any promise (86–98% at 50 mg/kg b.i.d.), paralleling efficacy trends in the mouse model. These results were also broadly in line with the hamster PK data, where **R-96** and **R-106** displayed inferior oral exposures and oral bioavailabilities (21–37%) much lower than those of the other leads [64–100% (Table 6 and Figure S2)].

To better discriminate among the four preferred candidates, we next considered key safety features, starting with measuring their interactions with the hERG channel. While the monoaryl ethers **R-6** and **R-136** posed minimal risk (hERG IC₅₀s of >30 μM), unfortunately, phenylpyridines **R-84** and **R-89** both caused potent inhibition (IC₅₀s of 0.81 and 0.92 μM , respectively), indicating a strong likelihood of QT prolongation⁵² (lead optimization criteria^{53,54} mandate an IC₅₀ of >10 μM). This outcome was not anticipated, as 6S counterparts had generated much less concern. The two remaining compounds

Table 6. Pharmacokinetic Parameters for Selected Compounds in Mice, Rats, and Hamsters

compd	intravenous (1–2 mg/kg) ^a					oral (25–50 mg/kg) ^a				
	C ₀ (μg/mL)	CL (mL/min/kg)	V _{dss} (L/kg)	t _{1/2} (h)	AUC _{last} ^b (μg·h/mL)	C _{max} (μg/mL)	T _{max} (h)	t _{1/2} (h)	AUC _{last} ^b (μg·h/mL)	F ^c (%)
Mice										
R-6						21	5.3	7.8	272	
24	0.34	13	2.5	2.0	1.25	1.5	1.0		15.7	50
R-84						16	4.7	9.4	211	
R-89						32	3.3	6.1	265	
116	0.75	1.2	1.9	20	11.7	0.87	10		32.2	11
117	0.44	5.2	1.8	2.7	3.18	0.84	8.0		12.0	15
R-136						96	3.1	30	1777	
Rats										
R-6	0.54	11	2.7	3.0	1.51	5.2	6.7	^d	80.6	100
R-136	0.84	6.1	1.5	2.7	2.47	18	2.7	3.5	164	100
Hamsters										
R-6	0.66	81	6.5	1.4	0.42	2.1	3.3	2.2	11.2	100
R-84	0.65	23	8.2	6.3	1.30	5.7	3.0	5.8	62.7	100
R-89	0.94	18	4.2	3.9	1.89	4.2	2.0	3.9	26.7	74
R-96	0.93	63	4.0	0.83	0.48	1.9	0.75	0.83	3.95	37
R-99	1.1	8.8	3.2	5.3	3.69	4.7	3.3	5.8	46.5	64
R-106	0.52	59	5.4	1.4	0.71	1.1	1.7	17	3.40	21
R-136						12	3.3	3.1	71.0	

^aThe intravenous dose was 1 mg/kg for mice and rats and 2 mg/kg for hamsters. The oral dose was 25 mg/kg for 24, 116, and 117, 50 mg/kg for R-106 and R-136, and 40 mg/kg for the other compounds. ^bArea under the curve calculated to the last time point (24 or 48 h). ^cOral bioavailability, determined using dose-normalized AUC_{last} values. ^dNot calculable.




Figure 3. Potencies of 17 selected phenotypic screening hits^{30,39,42,46–49} against *L. don* (percent inhibition data from IPK, IC₅₀s from CDRI).




Figure 4. Comparative *in vivo* efficacy in the *L. don* mouse model: (a) 25 mg/kg and (b) 6.25 mg/kg. All compounds except racemates 24, 116, and 117 are the 6R form.

Table 7. *In Vivo* Efficacy Data for Selected Compounds in the Early Curative *L. inf* Hamster Model

compd	dose ^a (mg/kg)	% inhibition in target organs ^b		
		liver	spleen	bone marrow
MIL	40	99.0	99.5	96.8
R-6	50	100	100	99.8
	25	98.4	99.2	97.0
	12.5	53.5	47.6	37.3
	50	100	99.9	99.9
R-84	25	98.1	98.4	88.3
	12.5	69.6	55.7	33.6
	50	99.9	99.9	98.9
R-89	25	99.1	93.7	81.3
	12.5	83.5	70.6	50.4
	50	73.0	55.1	55.7
R-96	50	97.7	97.5	86.0
R-99	50	55.7	17.6	45.0
R-106	50	100	100	99.9
	25	99.5	97.3	97.7
	12.5	44.4	43.0	53.0

^aAll test compounds were dosed orally, twice daily for 5 days consecutively; miltefosine (MIL) was dosed once daily for the same period. ^bData are the mean percentage reductions in parasite burden in target organs.

were then checked for any evidence of mutagenicity in the Ames test. Here, phenyl ether R-6 was negative, but the more soluble pyridinyl ether R-136 unexpectedly yielded a positive result. Although several other nitroimidazole drugs are Ames positive (e.g., metronidazole and fexinidazole),⁵⁵ this outcome effectively ruled R-136 out of contention because it would face a more difficult path to achieving regulatory approval.^{16,53} Thus, R-6 was identified as the optimal VL lead.

Further Appraisal of VL lead R-6. Additional properties of R-6 were measured and weighed against those of the initial preclinical candidate 4 (Table 8). The two compounds were comparable in terms of molecular weight (345 Da vs 359 Da) and were both highly permeable, but R-6 had a lower measured LogD value (2.59 vs 3.10 for 4 and 2.52 for S-1⁴⁸), superior thermodynamic solubility (23 μ M vs 2.8 μ M), and a reduced propensity to bind to plasma proteins in various species (82–87% vs 92–96% for 4). This lead also showed only weak CYP3A4 activity ($IC_{50} > 40 \mu$ M) and produced a notably favorable rat PK profile, with prolonged exposure and 100% oral bioavailability (Table 6 and Figure S2). These attributes reinforced our conclusion that R-6 (DNDI-8219) was indeed a very promising backup candidate for VL.

A larger scale synthesis of R-6 has recently provided a single 170 g batch of high-quality material (HPLC purity of >99.9% and 97.2% ee) in reasonable overall yield (8% over nine linear




Figure 5. Comparative *in vivo* efficacy in the *L. inf* hamster model. All compounds are the 6R form.

Table 8. Additional Comparative Data for Lead Compounds 4 and R-6

property	4 ^a	R-6
molecular weight (Da)	359.3	345.2
LogD (measured)	3.10	2.59
thermodynamic solubility (μM) at pH 7.4	2.8	23
permeability, Papp ($\times 10^{-6}$ cm/s) A to B/B to A	22.6/24.7 ^b	32.4/18.9 ^c
plasma protein binding (%)		
mouse	96.2	86.7
rat	93.2	82.1
hamster	92.4	87.2
human	93.9	85.2
mutagenic effect (Ames test)	no	no ^d
hERG IC ₅₀ (μM)	10.5	>30
CYP3A4 IC ₅₀ (μM)	>25	>40
MABA MIC (μM)	0.046	31 ^e
LORA MIC (μM)	5.9	>128

^aMost data from refs 24 and 25. ^bCaco-2 data from ref 61. ^cMDCK-MDR1 data; no P-gp-mediated efflux. ^dNot mutagenic in strains TA98 and TA100, in the presence or absence of metabolic activation (S9 fraction). ^eSingle MIC against *M. tb*, determined under aerobic conditions.

steps, starting from commercial *R*-solketal). However, the current synthetic route would still require significant improvement to deliver a scalable, robust, and cost-effective chemical process, in line with the stated TPP objectives for an affordable drug. Possible alternatives include using the known⁵⁶ enantiomer of orthogonally diprotected triol 125 and following the pathway described for *S*-6 in Scheme 4B because this enantiomer could be obtained from the cheap, optically pure starting material *D*-mannitol (via the less expensive *S*-solketal).⁵⁷

Mechanistic studies of the closely related nitroimidazooxazine *R*-1 demonstrated that it was not activated by the previously identified type I nitroreductase (NTR1) in *Leishmania*, which mediates the cidal effects of monocyclic nitroheterocyclic drugs such as fexinidazole and nifurtimox.^{38,58} Instead, the activity of *R*-1 was solely triggered by the same novel flavin mononucleotide-dependent NADH oxidoreductase (NTR2) in *Leishmania* that was employed by nitroimidazooxazoles, such as 4 and 5.²⁷ This new mode of action was elucidated through a combination of quantitative proteomics and whole genome sequencing of susceptible and drug resistant *L. don* promastigotes, the latter being generated via culture in the continuous presence of *R*-1 for 80 days (leading to a reduced level of expression of NTR2).²⁷ The further observation that *R*-1 and fexinidazole sulfone displayed additive effects against drug susceptible *L. don* sparked the suggestion of combination therapy between monocyclic and bicyclic nitro drugs to reduce the likelihood of any future clinical drug resistance.³⁸ However, we consider that it may be more preferable to look for alternative partner drugs for 3 (or *R*-6) with greater diversity in their mechanism of action.

One final aspect to consider with *R*-6 was its efficacy against a wider range of VL and cutaneous leishmaniasis (CL) strains. Overall, *R*-6 displayed potent broad-spectrum activity against both reference strains and clinical isolates (Table 9), comparing favorably with the standard agents sodium stibogluconate, paromomycin, and miltefosine. This lead was also effective against the drug resistant clinical isolates *L. don* BHU1, *L. inf* LEM5159, and *L. inf* MHOM/FR/96/LEM3323 (IC₅₀s of 1.3–

Table 9. Inhibitory Activity of *R*-6 and Clinical VL Drugs against Different *Leishmania* Strains

strain (origin)	IC ₅₀ (μM) ^a				
	R-6	SSG ^b	Amp B ^c	MIL ^d	PM ^e
VL Strains					
<i>L. don</i> MHOM/IN/80/DD8 (India)	0.22	54.3	0.02	2.50	>30
<i>L. don</i> MHOM/ET/67/HU3 (Ethiopia)	0.33	NT	0.05	2.05	NT
<i>L. inf</i> MHOM/MA/67/ITMAP263 (Morocco)	0.51	NT	NT	2.30	136
<i>L. don</i> MHOM/SD/62/ISCL2D (Sudan)	2.16	NT	NT	NT	NT
<i>L. inf</i> MHOM/FR/96/LEM3323 C14 MIL4 (France) ^f	0.59	NT	NT	>20	78.5
VL Clinical Isolates					
<i>L. don</i> BHU1 (India) ^g	1.34	>150	0.20	3.80	>30
<i>L. don</i> SUKA001 (Sudan)	0.57	29.9	0.05	2.13	>30
<i>L. don</i> GR265 (Ethiopia)	0.19	14.5	0.05	4.60	>30
<i>L. inf</i> LEMS695 (Algeria; dog)	1.77	NT	NT	1.86	165
<i>L. inf</i> MCAN/BR/2002/BH400 (Brazil; dog)	1.23	NT	NT	1.11	64.1
<i>L. inf</i> L3034 (Paraguay; HIV patient)	0.75	NT	NT	1.25	87.7
<i>L. inf</i> LEMS159 (France; HIV patient) ^{f,h}	5.41	NT	NT	>20	64.9
<i>L. inf</i> LEM3323 (France; HIV patient) ^h	2.22	NT	NT	0.74	142
CL Strains					
<i>Leishmania aethiopica</i> MHOM/ET/84/KH (Ethiopia)	3.17	NT	0.11	36.1	NT
<i>Leishmania amazonensis</i> MPRO/BR/72/M1841 (Brazil) ⁱ	4.68	NT	0.13	15.0	NT
<i>Leishmania major</i> MHOM/SA/85/JISH118 (Saudi Arabia)	2.34	NT	0.05	22.3	NT
<i>Leishmania mexicana</i> MNYC/BZ/62/M379 (Belize)	1.17	NT	0.08	6.55	NT
<i>Leishmania panamensis</i> MHOM/PA/67/Boynton (Panama)	0.34	NT	0.07	21.3	NT
<i>Leishmania tropica</i> Anwari (Syrian clinical isolate)	1.57	>100	0.11	8.22	NT

^aNT means not tested; some data for clinical VL drugs from refs 26 and 62. ^bSodium stibogluconate (IC₅₀ in micrograms per milliliter). ^cAmphotericin B. ^dMiltefosine. ^eParomomycin. ^fResistant to miltefosine. ^gResistant to sodium stibogluconate. ^hFailed amphotericin B treatment. ⁱDsRed2 transgenic strain.

5.4 μM), as well as the miltefosine resistant laboratory strain *L. inf* MHOM/FR/96/LEM3323 C14 MIL4 (IC₅₀ of 0.59 μM). These data confirm that *R*-6 has excellent potential as a therapy for VL and may have an additional application for the treatment of CL (the more common skin lesion form of leishmaniasis).¹

SAR of 6-Substituted 2-Nitroimidazo(or 2-Nitrotriazolo)oxazines for Chagas Disease. While the primary objective of this reinvestigation of pretomanid analogues was to develop a backup drug candidate for VL, retrospective screening against the protozoan parasites *T. cruzi* and *T. brucei* presented an opportunity to assess the possible capacity of these compounds to treat Chagas disease and human African trypanosomiasis (HAT), respectively. A brief inspection of Tables 1–4 found that only one compound (116) had submicromolar activity against HAT (*T. brucei* IC₅₀ of 0.63 μM), and this hit could be disregarded on the basis of its less favorable mouse PK profile, inferior aqueous solubility, and

poor MDCK-MDR1 cell permeability.³⁶ Conversely, like 7-substituted 2-nitroimidazooxazines,²⁴ the majority of compounds displayed interesting potencies against *T. cruzi* (IC₅₀s of 0.025–1 μ M). The selective anti-Chagas activity of nitrotriazolooxazines (e.g., **49**; *T. cruzi* IC₅₀ of 0.25 μ M vs >64 μ M against *L. inf*) was particularly striking, being reminiscent of that of a nitrotriazolooxazole analogue of **4**.²⁵ However, further scrutiny revealed that the enantiomers of **48** were roughly equipotent (Table 3), while the racemic nitrotriazole counterparts of key VL leads **R-6**, **R-84**, and **R-136** (**47**, **88**, and **139**, respectively) were 9–68-fold less active, suggesting limited utility for this class.

Aside from the less suitable reversed linker congeners (**24**–**26**, **116**, and **117**) and O-linked biaryls (**R-157**, **R-160**, **R-161**, **R-168**, and **R-171**), the most potent 6-substituted 2-nitroimidazooxazine anti-Chagas leads were *para*-linked phenylpyridines (e.g., **R-84**, **R-89**, **R-90**, **R-92**, and **R-93**; IC₅₀s of 0.025–0.078 μ M). Here, the 6*R* enantiomers were clearly superior (by 15- to >400-fold), and the 2-pyridine isomer was preferred, although N-oxidation of the pyridine ring (**R-85**) was strongly deactivating (77-fold). In the monoaryl subset, arylpropargyl ether **R-122** and phenyl ether **R-6** seemed highly promising (IC₅₀s of 0.11 and 0.15 μ M, respectively), with the latter favored on PK and solubility grounds, whereas similarly active benzylamines **R-148** and **R-149** were expected to show rapid metabolism.³⁶ Overall, given the significant hERG liability and higher level of plasma protein binding of the phenylpyridines (e.g., 97.9% for **R-84** in mice), **R-6** was also regarded as the best new lead for Chagas disease, although its mechanism of action for this application remains to be determined.

CONCLUSIONS

In response to a compelling clinical need for more satisfactory VL treatments, recent efforts have been made to reposition leads from other therapeutic areas, seeking to accelerate new drug development. Promising results with antitubercular nitroimidazooxazoles and 7-substituted 2-nitroimidazooxazines encouraged us to evaluate additional scaffolds, e.g., nitroimidazooxazepines and methylated or reversed C-6 linker analogues of pretomanid, but these lacked sufficient potency and/or suitable PK and efficacy in the *L. don* mouse model. However, phenotypic screening of our pretomanid analogue library and follow-up IC₅₀ testing unveiled more active hits spanning a wide lipophilicity range (CLogP values of 1.2–4.5), including several with better solubility and microsomal stability, e.g., phenylpyridines and benzamide **S-151**. This work also pointed to the generally improved activities of novel 6*R* enantiomers, which was confirmed for phenylpyridines through comparative appraisal in the mouse VL model. Further studies in this series established that a 4-trifluoromethoxy phenyl substituent, *para* linkage, and a proximal 2-pyridine ring were preferred for good *in vivo* PK and efficacy, with two such leads (**R-84** and **R-89**) giving $\geq 99\%$ parasite clearance in the *L. inf* hamster model at 50 mg/kg b.i.d. These compounds also showed high potencies against *T. cruzi*, but unexpectedly high levels of hERG inhibition ultimately terminated their development.

Meanwhile, investigation of the C-6 linker group revealed that the parent ether moiety in **R-1** (OCH₂) was nonoptimal for VL, with shorter and longer chain variants (O and OCH₂C $\equiv$ C, respectively) improving potency against *L. inf* (whereas O-carbamate and N-linked alternatives were poor). Although O-linked phenylpyridine **R-168** displayed superb

activity in the mouse VL model (99.7% reduction in parasite burden at 6.25 mg/kg, similar to the case for **4**), we elected to focus instead on two less lipophilic monoaryl leads (**R-6** and pyridine **R-136**), having superior solubility values (12–110 μ g/mL), low hERG risk, and excellent PK profiles in three species (mouse, rat, and hamster). Both compounds delivered high efficacies in the chronic infection hamster model ($\geq 97\%$ inhibition at 25 mg/kg, b.i.d.) and showed weakened binding to plasma proteins, although a positive Ames test for pyridine **R-136** dissuaded its further advancement and earmarked **R-6** as the favored VL backup candidate to **3**. Finally, like the phenylpyridines, **R-6** also demonstrated interesting activity against *T. cruzi*, whereas nitrotriazolooxazine congeners of such leads were less effective. These results provide new insights into the exciting potential of bicyclic nitroimidazoles as novel therapies for the treatment of some challenging neglected diseases.

EXPERIMENTAL SECTION

Combustion analyses were performed by the Campbell Micro-analytical Laboratory, University of Otago, Dunedin, New Zealand. Melting points were determined using an Electrothermal IA9100 melting point apparatus and are as read. NMR spectra were measured on a Bruker Avance 400 spectrometer at 400 MHz for ¹H and 100 MHz for ¹³C and were referenced to Me₄Si or solvent resonances. Chemical shifts and coupling constants were recorded in units of parts per million and hertz, respectively. High-resolution electron impact (HREIMS), chemical ionization (HRCIMS), and fast atom bombardment (HRFABMS) mass spectra were recorded on a VG-70SE mass spectrometer at a nominal 5000 resolution. High-resolution electrospray ionization (HRESIMS) mass spectrometry was conducted on a Bruker micrOTOF-Q II mass spectrometer. Low-resolution atmospheric-pressure chemical ionization (APCI) mass spectra were obtained for organic solutions using a ThermoFinnigan Surveyor MSQ mass spectrometer connected to a Gilson autosampler. Optical rotations were measured on a Schmidt + Haensch Polartronic NH8 polarimeter. Column chromatography was performed on silica gel (Merck 230–400 mesh). Chromatographed compounds were typically further purified by crystallization from two solvent combinations, e.g., CH₂Cl₂ and *n*-hexane, EtOAc and *n*-hexane, Et₂O and *n*-pentane, or CH₂Cl₂ and *n*-pentane (occasionally, Et₂O was added to the latter combination to induce solidification, while some compounds required cooling at –20 °C); more polar compounds were first dissolved in a minimum of 10% MeOH/CH₂Cl₂ and slowly diluted with *n*-hexane to give the solid product. Thin-layer chromatography was performed on aluminum-backed silica gel plates (Merck 60 F₂₅₄), with visualization of components by UV light (254 nm), I₂, or KMnO₄ staining. Tested compounds (including batches screened *in vivo*) were all $\geq 95\%$ pure, as determined by combustion analysis (results within 0.4% of theoretical values) and/or by HPLC conducted on an Agilent 1100 system with diode array detection, using a 150 mm $\times$ 3.2 mm Altima 5 μ m reversed phase C18 column or a 150 mm $\times$ 4.6 mm Zorbax Eclipse XDB 5 μ m C8 column and eluting with a gradient (40 to 100%) of 80% CH₃CN/water in 45 mM ammonium formate buffer (pH 3.5). Finally, the chiral purity of lead **R-6** was assessed by HPLC performed on a Shimadzu 2010 system with diode array detection, employing a 150 mm $\times$ 4.6 mm CHIRALPAK AY-H 5 μ m analytical column and isocratic elution with 20% EtOH/*n*-heptane.

Compounds of Table 1. The following section details the syntheses of compounds **14**, **39**, and **41** of Table 1, via representative procedures and key intermediates, as described in Scheme 1. For the syntheses of the other compounds in Table 1, see the Supporting Information.

Synthesis of 14 (Scheme 1A). Procedure A: 1-[(*tert*-Butyldimethylsilyl)oxy]-3-(2,4-dinitro-1*H*-imidazol-1-yl)-2-methylpropan-2-ol (**10**). A mixture of 2,4-dinitro-1*H*-imidazole (**8**) (1.00 g, 6.33 mmol) and *tert*-butyldimethyl[(2-methyloxiran-2-yl)methoxy]silane³³ (**9**) (1.81 g, 8.94 mmol) under N₂ was stirred at 75 °C for 18

h. The resulting cooled mixture was diluted with EtOAc (250 mL) and washed with aqueous NaHCO₃ (150 mL) and brine (125 mL), back-extracting with EtOAc (150 mL). The combined extracts were dried (Na₂SO₄) and then evaporated to dryness under reduced pressure, and the remaining oil was chromatographed on silica gel. Elution with 10–33% EtOAc/petroleum ether gave **10** (0.92 g, 40%) as a yellow oil: ¹H NMR (CDCl₃) δ 7.98 (s, 1 H), 4.75 (d, J = 14.0 Hz, 1 H), 4.53 (d, J = 14.0 Hz, 1 H), 3.54 (d, J = 10.2 Hz, 1 H), 3.46 (d, J = 10.1 Hz, 1 H), 2.52 (br s, 1 H), 1.17 (s, 3 H), 0.91 (s, 9 H), 0.09 (2 s, 2 × 3 H); HRCIMS (NH₃) calcd for C₁₃H₂₅N₄O₆Si m/z [M + H]⁺ 361.1543, found 361.1545.

Procedure B: 1-{3-[(*tert*-Butyldimethylsilyl)oxy]-2-methyl-2-[(*tetrahydro-2H-pyran-2-yl*)oxy]propyl}-2,4-dinitro-1H-imidazole (**11**). A mixture of alcohol **10** (248 mg, 0.688 mmol), 3,4-dihydro-2H-pyran (0.32 mL, 3.51 mmol), and PPTS (95 mg, 0.378 mmol) in anhydrous CH₂Cl₂ (10 mL) under N₂ was stirred at 20 °C for 5 h. The resulting solution was diluted with CH₂Cl₂ (100 mL) and washed with aqueous NaHCO₃ (2 × 50 mL), water (50 mL), and brine (50 mL), back-extracting with CH₂Cl₂ (50 mL). The combined extracts were dried (Na₂SO₄) and then evaporated to dryness under reduced pressure, and the remaining oil was chromatographed on silica gel. Elution with 10% EtOAc/petroleum ether gave **11** (234 mg, 76%) as a yellow oil (a 1:1 mixture of diastereomers): ¹H NMR (CDCl₃) δ 8.25, 7.99 (2 s, 1 H), 4.88 (d, J = 13.8 Hz, 0.5 H), 4.87 (d, J = 14.0 Hz, 0.5 H), 4.84–4.72 (m, 1 H), 4.62 (d, J = 14.0 Hz, 0.5 H), 4.54 (d, J = 13.8 Hz, 0.5 H), 3.73–3.65 (m, 1 H), 3.60–3.36 (m, 2 H), 3.29 (d, J = 10.6 Hz, 0.5 H), 3.26 (d, J = 10.7 Hz, 0.5 H), 1.95–1.35 (m, 6 H), 1.33, 1.25 (2 s, 3 H), 0.94, 0.87 (2 s, 9 H), 0.10 (2 s, 3 H), 0.04, 0.02 (2 s, 3 H); HRCIMS (NH₃) calcd for C₁₈H₃₃N₄O₇Si m/z [M + H]⁺ 445.2119, found 445.2125.

Procedure C: 6-Methyl-2-nitro-6-[(*tetrahydro-2H-pyran-2-yl*)oxy]-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazine (**12**). A solution of silyl ether **11** (230 mg, 0.517 mmol) in anhydrous THF (6 mL) under N₂ was treated with TBAF (1.5 mL of a 1 M solution in THF, 1.50 mmol), and the mixture was stirred at 20 °C for 1 h. The resulting solution was concentrated under reduced pressure, then diluted with EtOAc (50 mL), and washed with aqueous NaHCO₃ (50 mL) and brine (50 mL), back-extracting with EtOAc (2 × 50 mL). The combined extracts were dried (Na₂SO₄) and then evaporated to dryness under reduced pressure, and the residue was chromatographed on silica gel. Elution with 5% MeOH/CH₂Cl₂ gave **12** (130 mg, 89%) as a white solid (a 1:1 mixture of diastereomers): mp (CH₂Cl₂/hexane) 153–156 °C; ¹H NMR (CDCl₃) δ 7.40, 7.37 (2 s, 1 H), 5.03–4.95 (m, 1 H), 4.54 (dd, J = 11.6, 2.3 Hz, 0.5 H), 4.44 (dd, J = 11.8, 2.7 Hz, 0.5 H), 4.34 (dd, J = 12.7, 2.7 Hz, 0.5 H), 4.18 (d, J = 11.6 Hz, 0.5 H), 4.11 (d, J = 11.7 Hz, 0.5 H), 4.09 (dd, J = 12.5, 2.3 Hz, 0.5 H), 3.89 (d, J = 12.6 Hz, 0.5 H), 3.89–3.81 (m, 1 H), 3.57–3.44 (m, 1 H), 3.42–3.33 (m, 0.5 H), 1.92–1.38 (m, 9 H); APCI MS m/z 284 [M + H]⁺.

Procedure D: 6-Methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazin-6-ol (**13**). A solution of THP ether **12** (120 mg, 0.424 mmol) in MeOH (10 mL) was treated with methanesulfonic acid (52.6 mg, 0.547 mmol), and the mixture was stirred at 20 °C for 1 h. The resulting solution was neutralized with aqueous NaHCO₃; then the solvents were removed under reduced pressure, and the residue was chromatographed on silica gel. Elution with 5% MeOH/CH₂Cl₂ gave **13** (80 mg, 95%) as a white solid: mp (MeOH/CH₂Cl₂/hexane) 185–188 °C; ¹H NMR [(CD₃)₂SO] δ 8.05 (s, 1 H), 5.50 (br s, 1 H), 4.26 (d, J = 11.1 Hz, 1 H), 4.12 (dd, J = 11.1, 2.6 Hz, 1 H), 4.00 (d, J = 12.6 Hz, 1 H), 3.89 (dd, J = 12.6, 2.4 Hz, 1 H), 1.24 (s, 3 H); HREIMS calcd for C₇H₉N₃O₄ m/z (M⁺) 199.0593, found 199.0591.

Procedure E: 6-Methyl-2-nitro-6-[(4-(trifluoromethoxy)benzyl)oxy]-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazine (**14**). A solution of alcohol **13** (50.7 mg, 0.255 mmol) and 4-(trifluoromethoxy)benzyl bromide (65 μL, 0.406 mmol) in anhydrous DMF (3 mL) under N₂ was treated with 60% NaH (20 mg, 0.50 mmol), and the mixture was stirred at 20 °C for 3 h. The resulting mixture was diluted with EtOAc (150 mL) and washed with aqueous NaHCO₃ (50 mL), water (2 × 50 mL), and brine (50 mL), back-extracting with EtOAc (100 mL). The combined extracts were dried (Na₂SO₄) and then evaporated to

dryness under reduced pressure, and the residue was chromatographed on silica gel. Elution with 1–2% MeOH/CH₂Cl₂ gave **14** (45 mg, 47%) as a white solid: mp (EtOAc/hexane) 139–141 °C; ¹H NMR [(CD₃)₂SO] δ 7.99 (s, 1 H), 7.31 (br d, J = 9.0 Hz, 2 H), 7.28 (br d, J = 9.0 Hz, 2 H), 4.60 (dd, J = 11.9, 2.8 Hz, 1 H), 4.56 (br s, 2 H), 4.37 (d, J = 11.8 Hz, 1 H), 4.24 (dd, J = 13.2, 2.6 Hz, 1 H), 4.07 (d, J = 13.1 Hz, 1 H), 1.36 (s, 3 H); ¹³C NMR [(CD₃)₂SO] δ 147.5, 147.0, 142.2, 137.8, 129.0 (2 C), 120.9 (2 C), 120.0 (q, J_{C–F} = 255.9 Hz), 117.8, 70.6, 69.2, 62.9, 50.7, 17.0. Anal. Calcd for C₁₅H₁₄F₃N₃O₅: C, 48.26; H, 3.78; N, 11.26. Found: C, 48.23; H, 3.98; N, 11.31.

Synthesis of 39 and 41 (Scheme 1D). 2-Bromo-4-nitro-1-{3-[(*tetrahydro-2H-pyran-2-yl*)oxy]-4-[(*triisopropylsilyl*)oxy]butyl}-1H-imidazole (**35**). Reaction of 4-(2-bromo-4-nitro-1H-imidazol-1-yl)-1-[(*triisopropylsilyl*)oxy]butan-2-ol²⁴ (**34**) with 3,4-dihydro-2H-pyran (4.0 equiv) and PPTS, using procedure B for 1 day (but washing with aqueous NaHCO₃ only and extracting the product four times with CH₂Cl₂), followed by chromatography of the product on silica gel, eluting with 25–50% CH₂Cl₂/petroleum ether (forerunners) and then with CH₂Cl₂, gave **35** (100%) as a colorless oil (a 1:1 mixture of diastereomers): ¹H NMR (CDCl₃) δ 8.20, 7.82 (2 s, 1 H), 4.69–4.58 (m, 1 H), 4.31–4.10 (m, 2 H), 4.08–3.99 (m, 1 H), 3.92–3.43 (m, 4 H), 2.34–2.23 (m, 0.5 H), 2.12–2.01 (m, 1 H), 1.94–1.41 (m, 6.5 H), 1.18–0.96 (m, 21 H); HRFABMS calcd for C₂₁H₃₉BrN₃O₅Si m/z [M + H]⁺ 522.1822, 520.1842, found 522.1838, 520.1826.

4-(2-Bromo-4-nitro-1H-imidazol-1-yl)-2-[(*tetrahydro-2H-pyran-2-yl*)oxy]butan-1-ol (**36**). Reaction of silyl ether **35** with TBAF (1.1 equiv), using procedure C for 3 h (extracting the product five times with EtOAc), followed by chromatography of the product on silica gel, eluting with 33% EtOAc/petroleum ether (forerunners) and then with 33–50% EtOAc/petroleum ether, gave **36** (91%) as a white solid (a 3:1 mixture of diastereomers): mp (Et₂O/CH₂Cl₂/pentane) 89–91 °C; ¹H NMR (CDCl₃) δ 8.16, 7.79 (2 s, 1 H), 4.65–4.50 (m, 1 H), 4.29–4.12 (m, 2 H), 4.08–3.97 (m, 1 H), 3.85–3.46 (m, 4 H), 2.12–1.73 (m, 5 H), 1.65–1.45 (m, 4 H). Anal. Calcd for C₁₂H₁₈BrN₃O₅: C, 39.58; H, 4.98; N, 11.54. Found: C, 39.85; H, 5.12; N, 11.57.

Procedure F: 2-Nitro-7-[(*tetrahydro-2H-pyran-2-yl*)oxy]-5,6,7,8-tetrahydroimidazo[2,1-*b*][1,3]oxazepine (**37**). A solution of alcohol **36** (730 mg, 2.00 mmol) in anhydrous DMF (8 mL) under N₂ at 0 °C was treated with 60% NaH (148 mg, 3.70 mmol) and then quickly degassed and resealed under N₂. The mixture was stirred at 20 °C for 3.5 h and then cooled to –78 °C (CO₂/acetone), the reaction quenched with ice/aqueous NaHCO₃ (50 mL), and the mixture extracted with EtOAc (7 × 50 mL). The extracts were washed with brine (50 mL) and then evaporated to dryness under reduced pressure (at 30 °C), and the residue was chromatographed on silica gel. Elution with 0–33% EtOAc/petroleum ether first gave forerunners, and then further elution with 50% EtOAc/petroleum ether gave the crude product, which was chromatographed again on silica gel. Elution with 0–2% EtOAc/CH₂Cl₂ first gave forerunners, and then further elution with 3–4% EtOAc/CH₂Cl₂ gave **37** (144 mg, 25%) as a white solid: mp (CH₂Cl₂/hexane) 158–160 °C; ¹H NMR (CDCl₃) δ 7.48 (s, 1 H), 4.83–4.75 (m, 1 H), 4.39–4.04 (m, 4 H), 3.96–3.82 (m, 2 H), 3.60–3.50 (m, 1 H), 2.25–2.02 (m, 2 H), 1.92–1.71 (m, 2 H), 1.69–1.50 (m, 4 H). Anal. Calcd for C₁₂H₁₇N₃O₅: C, 50.88; H, 6.05; N, 14.83. Found: C, 51.08; H, 6.08; N, 14.89.

2-Nitro-5,6,7,8-tetrahydroimidazo[2,1-*b*][1,3]oxazepin-7-ol (**38**). A solution of THP ether **37** (137 mg, 0.484 mmol) in MeOH (14 mL) was treated with 3.3 M HCl (0.47 mL, 1.55 mmol). The mixture was stirred at 20 °C for 5 h, cooled to –20 °C, and neutralized with a solution of NH₃ in MeOH (0.8 mL of a 7 M solution). The resulting mixture was evaporated to dryness under reduced pressure (at 30 °C), and the residue was chromatographed on silica gel. Elution with 0–25% EtOAc/CH₂Cl₂ first gave forerunners, and then further elution with 25% EtOAc/CH₂Cl₂ gave **38** (91 mg, 94%) as a white solid: mp (MeOH/CH₂Cl₂/hexane) 185–187 °C; ¹H NMR [(CD₃)₂SO] δ 8.15 (s, 1 H), 5.28 (br s, 1 H), 4.22 (ddd, J = 14.1, 9.1, 2.0 Hz, 1 H), 4.19–4.09 (m, 1 H), 4.02–3.91 (m, 3 H), 2.09–1.98 (m, 1 H), 1.88–1.76 (m, 1 H). Anal. Calcd for C₇H₉N₃O₄: C, 42.21; H, 4.55; N, 21.10. Found: C, 42.41; H, 4.72; N, 21.28.

Procedure G: 2-Nitro-7-[[4-(trifluoromethoxy)benzyl]oxy]-5,6,7,8-tetrahydroimidazo[2,1-b][1,3]oxazepine (**39**) and 2-Nitro-7-[[4-(trifluoromethoxy)benzyl]oxy]methyl-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (**41**). A mixture of alcohol **38** (51.0 mg, 0.256 mmol) and 4-(trifluoromethoxy)benzyl bromide (0.205 mL, 1.28 mmol) in anhydrous DMF (1.5 mL) under N₂ at 0 °C was treated with 60% NaH (17.5 mg, 0.438 mmol) and then quickly degassed and resealed under N₂. The mixture was stirred at 20 °C for 130 min and then cooled to -78 °C (CO₂/acetone), the reaction quenched with ice/aqueous NaHCO₃ (10 mL), and the mixture added to brine (40 mL) and extracted with CH₂Cl₂ (5 × 50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C), and the residue was chromatographed on silica gel. Elution with 0–50% EtOAc/petroleum ether first gave forerunners, and then further elution with 50% EtOAc/petroleum ether gave **39** (37 mg, 39%) as a white solid: mp (CH₂Cl₂/pentane) 119–121 °C; ¹H NMR [(CD₃)₂SO] δ 8.18 (s, 1 H), 7.51 (br d, *J* = 8.8 Hz, 2 H), 7.36 (br d, *J* = 7.9 Hz, 2 H), 4.66 (s, 2 H), 4.36 (dd, *J* = 12.6, 4.6 Hz, 1 H), 4.26–4.13 (m, 2 H), 4.04 (ddd, *J* = 14.2, 6.4, 3.0 Hz, 1 H), 3.95–3.86 (m, 1 H), 2.19–2.02 (m, 2 H); ¹³C NMR [(CD₃)₂SO] δ 151.1, 147.6 (*q*, *J*_{C–F} = 1.5 Hz), 140.6, 137.9, 129.3 (2 C), 120.9 (2 C), 120.4, 120.1 (*q*, *J*_{C–F} = 256.1 Hz), 74.5, 73.3, 68.7, 42.0, 30.1. Anal. Calcd for C₁₅H₁₄F₃N₃O₅·0.5H₂O: C, 47.13; H, 3.96; N, 10.99. Found: C, 46.86; H, 3.63; N, 10.82. HPLC purity of 100%.

Further elution of the column described above with 50–75% EtOAc/petroleum ether gave crude **41**, which was chromatographed again on silica gel (as before) to give **41**²⁴ (34 mg, 36%) as a cream solid: mp (EtOAc/hexane) 163–164 °C (lit.²⁴ mp 158–160 °C); ¹H NMR (CDCl₃) δ 7.42 (s, 1 H), 7.34 (br d, *J* = 8.7 Hz, 2 H), 7.20 (br d, *J* = 8.6 Hz, 2 H), 4.61 (s, 2 H), 4.61–4.54 (m, 1 H), 4.15 (ddd, *J* = 12.4, 5.7, 3.7 Hz, 1 H), 4.06 (ddd, *J* = 12.4, 10.0, 5.8 Hz, 1 H), 3.83 (dd, *J* = 10.6, 4.4 Hz, 1 H), 3.78 (dd, *J* = 10.7, 4.9 Hz, 1 H), 2.39–2.21 (m, 2 H); APCI MS *m/z* 374 [M + H]⁺; HPLC purity of 100%.

Compounds of Table 2. The following section details the syntheses of compounds **R-58** and **R-69** of Table 2, via representative procedures and key intermediates, as described in Scheme 2. For the syntheses of the other compounds in Table 2, see the Supporting Information.

Synthesis of R-58 (Scheme 2A). (6*R*)-6-[(2-iodobenzyl)oxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazine (**57**). Reaction of (6*R*)-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazin-6-ol³² (**56**) with 2-iodobenzyl chloride (3.0 equiv) and NaH (1.6 equiv), using procedure G for 3.5 h, followed by chromatography of the product on silica gel, eluting with 0–0.25% MeOH/CH₂Cl₂ (forerunners) and then with 0.25–0.3% MeOH/CH₂Cl₂, gave **57** (91%) as a light yellow solid: mp (Et₂O) 118–119 °C; ¹H NMR (CDCl₃) δ 7.85 (br d, *J* = 7.8 Hz, 1 H), 7.40 (s, 1 H), 7.37–7.33 (m, 2 H), 7.08–7.00 (m, 1 H), 4.72 (d, *J* = 12.0 Hz, 1 H), 4.72–4.65 (m, 1 H), 4.64 (d, *J* = 12.0 Hz, 1 H), 4.40 (br dd, *J* = 12.1, 0.9 Hz, 1 H), 4.25–4.19 (m, 3 H). Anal. Calcd for C₁₃H₁₂IN₃O₄: C, 38.92; H, 3.02; N, 10.47. Found: C, 39.08; H, 2.98; N, 10.44.

Procedure H: (6*R*)-2-Nitro-6-[[4'-(trifluoromethoxy)(1,1'-biphenyl)-2-yl]methoxy]-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazine (**R-58**). A mixture of iodide **57** (435 mg, 1.08 mmol), [4-(trifluoromethoxy)phenyl]boronic acid (401 mg, 1.95 mmol), and Pd(dppf)Cl₂ (**56** mg, 0.077 mmol) in DMF (6 mL) and aqueous KHCO₃ (2 mL of a 2 M solution, 4.0 mmol) was degassed, and then N₂ was added. The resulting mixture was stirred at 75 °C for 4 h, and then cooled, diluted with brine (100 mL), and extracted with CH₂Cl₂ (3 × 100 mL). The extracts were evaporated to dryness under reduced pressure, and the residue was chromatographed on silica gel. Elution with CH₂Cl₂ first gave forerunners, and then further elution with 2% MeOH/CH₂Cl₂ gave **R-58** (218 mg, 46%) as a cream solid: mp (CH₂Cl₂/hexane) 133–135 °C; ¹H NMR [(CD₃)₂SO] δ 8.00 (s, 1 H), 7.50–7.44 (m, 3 H), 7.44–7.35 (m, 4 H), 7.33–7.26 (m, 1 H), 4.57–4.49 (m, 2 H), 4.49 (d, *J* = 10.9 Hz, 1 H), 4.42 (br d, *J* = 11.8 Hz, 1 H), 4.22–4.12 (m, 3 H); ¹³C NMR [(CD₃)₂SO] δ 147.6 (*q*, *J*_{C–F} = 1.5 Hz), 147.1, 142.1, 140.0, 139.3, 134.5, 130.7 (2 C), 130.0, 129.9, 128.3, 127.9, 120.6 (2 C), 120.1 (*q*, *J*_{C–F} = 256.4 Hz), 117.9,

68.1, 67.8, 66.8, 46.5. Anal. Calcd for C₂₀H₁₆F₃N₃O₅: C, 55.18; H, 3.70; N, 9.65. Found: C, 55.08; H, 3.66; N, 9.68.

Synthesis of R-69 (Scheme 2B). (6*R*)-6-[(2-Bromopyridin-3-yl)methoxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazine (**68**). Reaction of alcohol **56**³² with 2-bromo-3-(bromomethyl)pyridine (**66**) (1.6 equiv) and NaH (1.6 equiv), using procedure G at 0 °C for 1 h and then at 20 °C for 80 min, followed by chromatography of the product on silica gel, eluting with 0–0.5% MeOH/CH₂Cl₂ (forerunners) and then with 0.5–0.67% MeOH/CH₂Cl₂, gave **68** (83%) as a cream solid: mp (MeOH/CH₂Cl₂/hexane) 189–190 °C; ¹H NMR [(CD₃)₂SO] δ 8.32 (dd, *J* = 4.7, 2.0 Hz, 1 H), 8.05 (s, 1 H), 7.80 (dd, *J* = 7.5, 2.0 Hz, 1 H), 7.46 (dd, *J* = 7.5, 4.7 Hz, 1 H), 4.73–4.66 (m, 3 H), 4.51 (br d, *J* = 11.7 Hz, 1 H), 4.39–4.32 (m, 2 H), 4.25 (dd, *J* = 13.7, 3.4 Hz, 1 H). Anal. Calcd for C₁₂H₁₁BrN₄O₄: C, 40.58; H, 3.12; N, 15.78. Found: C, 40.81; H, 3.20; N, 15.72.

Procedure I: (6*R*)-2-Nitro-6-[(2-[4-(trifluoromethoxy)phenyl]pyridin-3-yl)methoxy]-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazine (**R-69**). A stirred mixture of bromide **68** (60.3 mg, 0.170 mmol), [4-(trifluoromethoxy)phenyl]boronic acid (60.5 mg, 0.294 mmol), and Pd(dppf)Cl₂ (29.7 mg, 0.041 mmol) in DMF (1.5 mL), toluene (1.0 mL), and EtOH (0.8 mL) was degassed for 7 min (vacuum pump), and then N₂ was added. An aqueous solution of Na₂CO₃ (0.45 mL of a 2 M solution, 0.90 mmol) was added by syringe; the stirred mixture was again degassed for 8 min, and then N₂ was added. The resulting mixture was stirred at 87 °C for 190 min and then cooled, diluted with aqueous NaHCO₃ (50 mL), and extracted with CH₂Cl₂ (5 × 50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C), and the residue was chromatographed on silica gel. Elution with 0–0.5% MeOH/CH₂Cl₂ first gave forerunners, and then further elution with 0.5–0.75% MeOH/CH₂Cl₂ gave **R-69** (62 mg, 84%) as a pale yellow solid: mp (MeOH/CH₂Cl₂/hexane) 246–248 °C; ¹H NMR [(CD₃)₂SO] δ 8.62 (dd, *J* = 4.7, 1.7 Hz, 1 H), 8.02 (s, 1 H), 7.89 (dd, *J* = 7.8, 1.6 Hz, 1 H), 7.67 (br d, *J* = 8.8 Hz, 2 H), 7.43 (dd, *J* = 7.7, 4.8 Hz, 1 H), 7.41 (br d, *J* = 9.0 Hz, 2 H), 4.68–4.57 (m, 3 H), 4.46 (br d, *J* = 11.9 Hz, 1 H), 4.31–4.17 (m, 3 H); ¹³C NMR [(CD₃)₂SO] δ 156.2, 148.9, 148.4, 147.1, 142.1, 138.5, 138.2, 130.8 (2 C), 130.5, 122.8, 120.4 (2 C), 120.1 (*q*, *J*_{C–F} = 256.4 Hz), 118.0, 67.8, 67.4, 67.1, 46.6. Anal. Calcd for C₁₉H₁₅F₃N₄O₅: C, 52.30; H, 3.47; N, 12.84. Found: C, 52.02; H, 3.43; N, 12.72.

Compounds of Table 3. The following section details the syntheses of compounds **R-122**, **R-136**, **R-140**, **R-147**, **R-151**, and **R-155** of Table 3, via representative procedures and key intermediates, as described in Schemes 4 and 5. For the syntheses of the other compounds in Table 3, see the Supporting Information.

Synthesis of R-122 (Scheme 4A). (6*R*)-2-Nitro-6-[(prop-2-yn-1-yl)oxy]-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazine (**121**). A solution of alcohol **56**³² (430 mg, 2.32 mmol) and (3-bromoprop-1-yn-1-yl)(*tert*-butyl)dimethylsilane⁴¹ (**120**) (900 mg, 3.86 mmol) in anhydrous DMF (6 mL) under N₂ was treated with 60% NaH (148 mg, 3.70 mmol), and the mixture was stirred at 20 °C for 15 min. The resulting mixture was diluted with water (100 mL), and the precipitate was collected by filtration, washed with water and petroleum ether, and dried. This solid was then redissolved in THF (10 mL); TBAF (6.0 mL of a 1 M solution in THF, 6.0 mmol) was added, and the mixture was stirred at 20 °C for 30 min. The resulting mixture was diluted with EtOAc (100 mL) and washed with water (2 × 100 mL) and brine (100 mL), back-extracting with EtOAc (100 mL). The combined extracts were dried (Na₂SO₄) and then evaporated to dryness under reduced pressure, and the residue was chromatographed on silica gel. Elution with 50% EtOAc/petroleum ether first gave forerunners, and then further elution with EtOAc gave **121** (312 mg, 60%) as a cream solid: mp (Et₂O/pentane) 81–83 °C; ¹H NMR (CDCl₃) δ 7.42 (s, 1 H), 4.63 (ddd, *J* = 12.5, 3.8, 2.1 Hz, 1 H), 4.42–4.33 (m, 3 H), 4.32 (dd, *J* = 16.5, 2.5 Hz, 1 H), 4.25 (dd, *J* = 13.1, 3.6 Hz, 1 H), 4.18 (dt, *J* = 13.0, 2.5 Hz, 1 H), 2.56 (t, *J* = 2.4 Hz, 1 H); HRESIMS calcd for C₉H₉N₃NaO₄ *m/z* [M + Na]⁺ 246.0485, found 246.0484.

Procedure J: (6*R*)-2-Nitro-6-[(3-[4-(trifluoromethoxy)phenyl]prop-2-yn-1-yl)oxy]-6,7-dihydro-5H-imidazo[2,1-*b*][1,3]oxazine (**R-122**). A mixture of alkyne **121** (108 mg, 0.484 mmol), 1-iodo-4-(trifluoromethoxy)benzene (167 mg, 0.580 mmol), and CuI (2 mg,

0.01 mmol) in triethylamine (5 mL) and DMF (5 mL) was purged with N₂. Pd(PPh₃)₂Cl₂ (7 mg, 0.01 mmol) was added, and the mixture was stirred at 70 °C for 15 min under N₂ and then cooled, diluted with water (100 mL), and extracted with EtOAc (2 × 100 mL). The extracts were combined and evaporated to dryness under reduced pressure, and the residue was chromatographed on silica gel. Elution with 50% EtOAc/petroleum ether first gave forerunners, and then further elution with EtOAc gave **R-122** (109 mg, 59%) as a cream solid: mp 150–152 °C; ¹H NMR [(CD₃)₂SO] δ 8.05 (s, 1 H), 7.61 (br d, *J* = 8.9 Hz, 2 H), 7.39 (br d, *J* = 8.9 Hz, 2 H), 4.66 (dt, *J* = 12.1, 2.4 Hz, 1 H), 4.59 (s, 2 H), 4.49 (br d, *J* = 12.0 Hz, 1 H), 4.41–4.37 (m, 1 H), 4.31 (dt, *J* = 13.6, 2.0 Hz, 1 H), 4.25 (dd, *J* = 13.6, 3.2 Hz, 1 H); ¹³C NMR [(CD₃)₂SO] δ 148.3 (q, *J*_{C–F} = 1.5 Hz), 147.0, 142.1, 133.6 (2 C), 121.3 (2 C), 121.0, 119.9 (q, *J*_{C–F} = 257.1 Hz), 118.0, 86.5, 84.7, 67.8, 66.2, 56.2, 46.6. Anal. Calcd for C₁₆H₁₂F₃N₃O₅: C, 50.14; H, 3.16; N, 10.96. Found: C, 50.19; H, 3.08; N, 10.85.

Synthesis of R-136 (Scheme 4D). (6*R*)-2-Nitro-6-[[5-(trifluoromethyl)pyridin-2-yl]oxy]-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazine (**R-136**). A solution of alcohol **56**³² (1.00 g, 5.40 mmol) and 2-fluoro-5-(trifluoromethyl)pyridine (265 mg, 1.61 mmol) in anhydrous DMF (20 mL) under N₂ at –10 °C was treated with 60% NaH (275 mg, 6.88 mmol), then quickly degassed, and resealed under N₂. Then 2-fluoro-5-(trifluoromethyl)pyridine (1.32 g, 8.00 mmol) was added, and the mixture was stirred at –10 to 0 °C for 1 h. Additional 2-fluoro-5-(trifluoromethyl)pyridine (450 mg, 2.73 mmol) was added, and the mixture was stirred at 20 °C for 130 min. The resulting mixture was cooled to –78 °C (CO₂/acetone), the reaction quenched with ice/aqueous NaHCO₃ (20 mL), and then the mixture added to brine (100 mL) and extracted with CH₂Cl₂ (7 × 100 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C), and the residue was chromatographed on silica gel. Elution with CH₂Cl₂ first gave forerunners, and then further elution with 0–2% EtOAc/CH₂Cl₂ gave the product, which was triturated in Et₂O (10 mL) and diluted with pentane (90 mL) to give **R-136** (1.66 g, 93%) as a cream solid: mp 140–141 °C; ¹H NMR [(CD₃)₂SO] δ 8.68–8.64 (m, 1 H), 8.13 (br dd, *J* = 8.7, 2.6 Hz, 1 H), 8.05 (s, 1 H), 7.09 (d, *J* = 8.7 Hz, 1 H), 5.86–5.79 (m, 1 H), 4.75 (dt, *J* = 12.3, 2.1 Hz, 1 H), 4.71 (br d, *J* = 12.2 Hz, 1 H), 4.49 (dd, *J* = 14.0, 3.4 Hz, 1 H), 4.42 (br d, *J* = 14.1 Hz, 1 H); ¹³C NMR [(CD₃)₂SO] δ 163.9, 146.9, 144.8 (q, *J*_{C–F} = 4.5 Hz), 142.1, 137.2 (q, *J*_{C–F} = 3.1 Hz), 124.0 (q, *J*_{C–F} = 271.5 Hz), 119.7 (q, *J*_{C–F} = 32.6 Hz), 118.0, 112.1, 68.3, 64.3, 46.6. Anal. Calcd for C₁₂H₉F₃N₄O₄: C, 43.65; H, 2.75; N, 16.97. Found: C, 43.80; H, 2.69; N, 17.18.

Synthesis of R-140 (Scheme 4E). **Procedure K:** (6*R*)-2-Nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-6-yl [4-(trifluoromethoxy)phenyl]carbamate (**R-140**). 1-Isocyanato-4-(trifluoromethoxy)benzene (70 μL, 0.464 mmol) and CuCl (3.3 mg, 0.033 mmol) were successively added to a solution of alcohol **56**³² (54.2 mg, 0.293 mmol) in anhydrous DMF (0.7 mL) under N₂. The mixture was briefly degassed and resealed under N₂ and then stirred at 20 °C for 33 h. The resulting solution was treated with ice/water (5 mL), added to brine (50 mL), and extracted with CH₂Cl₂ (6 × 50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C), and the residue was chromatographed on silica gel. Elution with 0–3% EtOAc/CH₂Cl₂ first gave forerunners, and then further elution with 3–4% EtOAc/CH₂Cl₂ gave **R-140** (108 mg, 95%) as a cream solid: mp (CH₂Cl₂/hexane) 203–205 °C; ¹H NMR [(CD₃)₂SO] δ 10.11 (br s, 1 H), 8.09 (s, 1 H), 7.56 (br d, *J* = 8.8 Hz, 2 H), 7.30 (br d, *J* = 8.6 Hz, 2 H), 5.47–5.41 (m, 1 H), 4.69–4.60 (m, 2 H), 4.43 (dd, *J* = 14.0, 3.4 Hz, 1 H), 4.33 (br dd, *J* = 14.0, 1.1 Hz, 1 H); ¹³C NMR [(CD₃)₂SO] δ 152.2, 146.8, 143.3 (q, *J*_{C–F} = 1.6 Hz), 142.1, 137.9, 121.7 (2 C), 120.1 (q, *J*_{C–F} = 255.5 Hz), 119.6 (2 C), 117.9, 68.5, 62.9, 47.0. Anal. Calcd for C₁₄H₁₁F₃N₄O₆: C, 43.31; H, 2.86; N, 14.43. Found: C, 43.43; H, 2.73; N, 14.35.

Syntheses of R-147 and R-151 (Scheme 5A). (6*S*)-2-Nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-6-yl 4-methylbenzene-1-sulfonate (**144**). A mixture of (6*S*)-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-6-ol³² (**65**) (5.00 g, 27.0 mmol) and 4-methylbenzene-1-sulfonyl chloride (10.4 g, 54.6 mmol) in anhydrous pyridine (25 mL) was stirred at 49 °C for 17 h. The cooled solution was added to

crushed ice (~0.7 L), and the resulting precipitate was collected by filtration, washing with water and petroleum ether, to give **144** (8.62 g, 94%) as a cream solid: mp 238–242 °C dec; ¹H NMR [(CD₃)₂SO] δ 8.01 (s, 1 H), 7.85 (br d, *J* = 8.3 Hz, 2 H), 7.51 (br d, *J* = 8.0 Hz, 2 H), 5.41–5.34 (m, 1 H), 4.56 (br d, *J* = 12.3 Hz, 1 H), 4.42 (dt, *J* = 12.6, 2.6 Hz, 1 H), 4.35 (dd, *J* = 14.3, 3.2 Hz, 1 H), 4.20 (dt, *J* = 14.4, 1.9 Hz, 1 H), 2.44 (s, 3 H). Anal. Calcd for C₁₃H₁₃N₃O₆S: C, 46.02; H, 3.86; N, 12.38. Found: C, 46.25; H, 3.74; N, 12.47.

(6*R*)-6-Azido-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazine (145). A mixture of tosylate **144** (8.61 g, 25.4 mmol) and sodium azide (2.48 g, 38.1 mmol) in anhydrous DMSO (60 mL) was stirred at 64 °C for 84 h. The resulting cooled solution was added to water (250 mL) and extracted with EtOAc (5 × 250 mL); the initially formed emulsion required filtration to remove a dark brown tar. The combined extracts were evaporated to dryness under reduced pressure (at 50 °C), and the residue was triturated in EtOAc (45 mL), diluted with petroleum ether (15 mL), and filtered to give **145** (3.54 g, 66%) as a brown solid. The filtrate was evaporated to dryness under reduced pressure, and the residue was chromatographed on silica gel. Elution with 0–0.33% MeOH/CH₂Cl₂ first gave forerunners, and then further elution with 0.33–0.5% MeOH/CH₂Cl₂ gave crude **145**, which was chromatographed again on silica gel. Elution with Et₂O first gave forerunners, and then further elution with 0–0.33% MeOH/CH₂Cl₂ gave additional **145** (363 mg, 7%) as a cream solid: mp (EtOAc/hexane) 154–156 °C; ¹H NMR [(CD₃)₂SO] δ 8.08 (s, 1 H), 4.67–4.61 (m, 1 H), 4.59 (br dd, *J* = 11.9, 1.4 Hz, 1 H), 4.55 (ddd, *J* = 11.9, 2.8, 2.0 Hz, 1 H), 4.32 (dd, *J* = 13.5, 3.8 Hz, 1 H), 4.17 (br dt, *J* = 13.5, 1.8 Hz, 1 H); [α]_D²⁵ 92.6 (c 1.004, DMF). Anal. Calcd for C₆H₆N₆O₃: C, 34.29; H, 2.88; N, 39.99. Found: C, 34.57; H, 2.66; N, 40.03.

(6*R*)-2-Nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-6-amine Hydrochloride (146). Propane-1,3-dithiol (9.2 mL, 91.6 mmol) was added to a mixture of azide **145** (3.83 g, 18.2 mmol) and triethylamine (12.8 mL, 91.8 mmol) in anhydrous MeOH (75 mL) under N₂. After being stirred at 20 °C for 30 min, the mixture was evaporated to dryness under reduced pressure (at 30 °C), and the residue was chromatographed on silica gel. Elution with 0–3.5% MeOH/CH₂Cl₂ first gave forerunners, and then further elution with 5–8% MeOH/CH₂Cl₂ gave the product free base (2.25 g, 67%) as a yellow solid, which was used directly: ¹H NMR [(CD₃)₂SO] δ 8.06 (s, 1 H), 4.35 (br dd, *J* = 10.8, 2.1 Hz, 1 H), 4.19–4.10 (m, 2 H), 3.76 (ddd, *J* = 12.4, 5.5, 1.0 Hz, 1 H), 3.54–3.13 (m, 3 H); APCI MS *m/z* 185 [M + H]⁺. This free base was dissolved in MeOH (10 mL) and dioxane (10 mL) and treated with a solution of HCl in dioxane (4.6 mL of a 4 M solution, 18.4 mmol), and then the mixture was diluted with Et₂O (100 mL). The resulting oily precipitate was triturated to give **146** (2.29 g, 57%) as a bright yellow powder: mp 208 °C dec; ¹H NMR [(CD₃)₂SO] δ 8.73 (br s, 3 H), 8.18 (s, 1 H), 4.63 (dd, *J* = 12.2, 2.0 Hz, 1 H), 4.59 (dt, *J* = 12.1, 2.2 Hz, 1 H), 4.41 (dd, *J* = 14.0, 5.0 Hz, 1 H), 4.21 (br d, *J* = 14.1 Hz, 1 H), 4.16–4.07 (m, 1 H); [α]_D²⁷ 74.7 (c 1.004, H₂O); HRESIMS calcd for C₆H₉N₄O₃ *m/z* [M – Cl]⁺ 185.0669, found 185.0673.

Procedure L: (6*R*)-2-Nitro-*N*-[4-(trifluoromethoxy)benzyl]-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazin-6-amine (**R-147**). 4-(Trifluoromethoxy)benzaldehyde (130 μL, 0.910 mmol) was added to a mixture of amine salt **146** (120 mg, 0.544 mmol) and AcOH (65 μL, 1.14 mmol) in anhydrous DMF (5 mL) under N₂. The mixture was stirred at 20 °C for 15 min and then cooled to 0 °C. Sodium cyanoborohydride (73 mg, 1.16 mmol) was added, and the mixture was quickly degassed and resealed under N₂ and then stirred at 20 °C for 7 h. The resulting mixture was cooled to –78 °C (CO₂/acetone), the reaction quenched with ice/aqueous Na₂CO₃ (10 mL), and the mixture added to brine (40 mL) and extracted with CH₂Cl₂ (6 × 50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C), and the residue was chromatographed on silica gel. Elution with 0–0.25% MeOH/CH₂Cl₂ first gave forerunners, and then further elution with 0.33–0.5% MeOH/CH₂Cl₂ gave **R-147** (150 mg, 77%) as a cream solid: mp (Et₂O/CH₂Cl₂/hexane) 120–121 °C; ¹H NMR [(CD₃)₂SO] δ 8.01 (s, 1 H), 7.45 (br d, *J* = 8.6 Hz, 2 H), 7.30 (br d, *J* = 8.0 Hz, 2 H), 4.43 (dd, *J* = 11.2, 2.2 Hz, 1 H), 4.38 (ddd, *J* = 11.3, 4.3, 1.3 Hz, 1 H), 4.16 (dd, *J* = 12.7, 4.1 Hz, 1 H), 3.99

(dd, $J = 12.7, 2.7$ Hz, 1 H), 3.81 (br s, 2 H), 3.29–3.19 (m, 1 H), 2.83 (br s, 1 H); ^{13}C NMR $[(\text{CD}_3)_2\text{SO}]$ δ 147.4, 147.1, 142.1, 139.9, 129.6 (2 C), 120.8 (2 C), 120.1 (q, $J_{\text{C-F}} = 255.6$ Hz), 118.1, 68.8, 48.8, 47.2, 46.8. Anal. Calcd for $\text{C}_{14}\text{H}_{13}\text{F}_3\text{N}_4\text{O}_4$: C, 46.93; H, 3.66; N, 15.64. Found: C, 47.12; H, 3.54; N, 15.89.

Procedure M: *N*-[(6*R*)-2-Nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*]-[1,3]oxazin-6-yl]-3-(trifluoromethoxy)benzamide (**R-151**). 3-(Trifluoromethoxy)benzoyl chloride (205 mg, 0.913 mmol) was added to a solution of amine salt **146** (152 mg, 0.689 mmol) and DIPEA (0.30 mL, 1.72 mmol) in anhydrous DMF (3 mL) under N_2 . The mixture was stirred at 20 °C for 10 h and then treated with ice/water (5 mL), added to brine (40 mL), and extracted with CH_2Cl_2 (4 $\times$ 50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C), and the residue was chromatographed on silica gel. Elution with 0–0.5% MeOH/ CH_2Cl_2 first gave forerunners, and then further elution with 0.5–0.67% MeOH/ CH_2Cl_2 gave **R-151** (213 mg, 83%) as a cream solid: mp (Et_2O /pentane) 98–101 °C dec; ^1H NMR $[(\text{CD}_3)_2\text{SO}]$ δ 9.01 (br d, $J = 6.4$ Hz, 1 H), 8.13 (s, 1 H), 7.90 (dt, $J = 7.6, 1.3$ Hz, 1 H), 7.83–7.78 (m, 1 H), 7.63 (dd, $J = 8.0, 7.7$ Hz, 1 H), 7.60–7.55 (m, 1 H), 4.69–4.61 (m, 1 H), 4.57 (dd, $J = 11.2, 2.3$ Hz, 1 H), 4.51 (ddd, $J = 11.3, 4.1, 1.4$ Hz, 1 H), 4.41 (dd, $J = 13.0, 5.1$ Hz, 1 H), 4.17 (ddd, $J = 13.1, 3.3, 1.2$ Hz, 1 H); ^{13}C NMR $[(\text{CD}_3)_2\text{SO}]$ δ 165.4, 148.2, 147.2, 142.2, 135.9, 130.5, 126.8, 124.1, 120.1, 120.0 (q, $J_{\text{C-F}} = 256.8$ Hz), 118.4, 68.5, 46.5, 41.6. Anal. Calcd for $\text{C}_{14}\text{H}_{11}\text{F}_3\text{N}_4\text{O}_5$: C, 45.17; H, 2.98; N, 15.05. Found: C, 45.37; H, 2.98; N, 15.07.

Synthesis of R-155 (Scheme 5B). **Procedure N:** *N*-[(6*R*)-2-Nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*]-[1,3]oxazin-6-yl]-*N'*-[2-(trifluoromethoxy)phenyl]urea (**R-155**). 1-Isocyanato-2-(trifluoromethoxy)benzene (80 μL , 0.532 mmol) was added to a solution of amine salt **146** (80.2 mg, 0.364 mmol), DIPEA (0.155 mL, 0.890 mmol), and dibutyltin diacetate (9.3 mg, 0.026 mmol) in anhydrous DMF (2 mL) under N_2 . The mixture was stirred at 20 °C for 18 h and then treated with ice/water (5 mL), added to brine (40 mL), and extracted with CH_2Cl_2 (5 $\times$ 50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C), and the residue was chromatographed on silica gel. Elution with 0–0.5% MeOH/ CH_2Cl_2 first gave forerunners, and then further elution with 0.75–1% MeOH/ CH_2Cl_2 gave **R-155** (118 mg, 84%) as a cream solid: mp (MeOH/ CH_2Cl_2 /hexane) 221–225 °C dec; ^1H NMR $[(\text{CD}_3)_2\text{SO}]$ δ 8.27 (dd, $J = 8.5, 1.6$ Hz, 1 H), 8.26 (br s, 1 H), 8.11 (s, 1 H), 7.58 (br d, $J = 7.0$ Hz, 1 H), 7.35–7.25 (m, 2 H), 7.03 (ddd, $J = 8.0, 7.7, 1.6$ Hz, 1 H), 4.59 (dd, $J = 11.3, 1.8$ Hz, 1 H), 4.48 (ddd, $J = 11.3, 3.0, 2.2$ Hz, 1 H), 4.44–4.36 (m, 1 H), 4.31 (dd, $J = 12.8, 4.1$ Hz, 1 H), 4.12 (dt, $J = 12.9, 2.1$ Hz, 1 H); ^{13}C NMR $[(\text{CD}_3)_2\text{SO}]$ δ 154.2, 147.0, 142.1, 136.7, 132.5, 127.8, 122.1, 121.1, 120.3, 120.2 (q, $J_{\text{C-F}} = 257.6$ Hz), 118.4, 69.7, 47.8, 41.0. Anal. Calcd for $\text{C}_{14}\text{H}_{12}\text{F}_3\text{N}_5\text{O}_5$: C, 43.42; H, 3.12; N, 18.08. Found: C, 43.48; H, 2.99; N, 18.03.

Compounds of Table 4. The following section details the synthesis of compound **R-168** of Table 4, via representative procedures and key intermediates, as described in Scheme 5. For the syntheses of the other compounds in Table 4, see the Supporting Information.

Synthesis of R-168 (Scheme 5D). (2*R*)-2-[(6-bromopyridin-3-yl)oxy]-3-[(4-methoxybenzyl)oxy]propan-1-ol (**163**). Reaction of 2-bromo-5-[(2*S*)-1-[(4-methoxybenzyl)oxy]-3-[(triisopropylsilyl)oxy]propan-2-yl]oxy]pyridine⁴² (**162**) with TBAF (1.2 equiv), using procedure C for 13 h (extracting the product four times with EtOAc), followed by chromatography of the product on silica gel, eluting with 0–30% Et_2O /petroleum ether and CH_2Cl_2 (forerunners) and then with 2% MeOH/ CH_2Cl_2 , gave **163** (94%) as a white solid: mp (CH_2Cl_2 /pentane) 78–80 °C; ^1H NMR (CDCl_3) δ 8.12 (br d, $J = 3.0$ Hz, 1 H), 7.35 (br d, $J = 8.7$ Hz, 1 H), 7.20 (br d, $J = 8.8$ Hz, 2 H), 7.18 (dd, $J = 8.7, 3.1$ Hz, 1 H), 6.87 (br d, $J = 8.7$ Hz, 2 H), 4.51–4.42 (m, 3 H), 3.94–3.81 (m, 2 H), 3.81 (s, 3 H), 3.67 (d, $J = 5.1$ Hz, 2 H), 1.95 (t, $J = 6.4$ Hz, 1 H); $[\alpha]_D^{23}$ 19.8 (c 3.024, CHCl_3). Anal. Calcd for $\text{C}_{16}\text{H}_{18}\text{BrNO}_4$: C, 52.19; H, 4.93; N, 3.80. Found: C, 52.19; H, 4.82; N, 3.84.

Procedure O: 2-Bromo-5-[(2*S*)-1-iodo-3-[(4-methoxybenzyl)oxy]propan-2-yl]oxy]pyridine (**164**). A solution of iodine (3.74 g, 14.7 mmol) in anhydrous CH_2Cl_2 (9 $\times$ 10 mL) was slowly added (dropwise over 1 h) to a stirred mixture of alcohol **163** (3.97 g, 10.8 mmol), imidazole (1.92 g, 28.2 mmol), and triphenylphosphine (3.70 g, 14.1 mmol) in anhydrous CH_2Cl_2 (50 mL) under N_2 at 20 °C (water bath cooling). After being stirred at 20 °C for 41 h, the mixture was concentrated under reduced pressure (at 25 °C), and the residual oil was added to excess petroleum ether (100 mL) at the top of a silica gel column (50 g in petroleum ether), rinsing on with CH_2Cl_2 (4 $\times$ 5 mL). Elution with 0–10% Et_2O /petroleum ether first gave forerunners, and then further elution with 20–33% Et_2O /petroleum ether gave **164** (5.17 g, 100%) as a colorless oil: ^1H NMR (CDCl_3) δ 8.11 (d, $J = 3.1$ Hz, 1 H), 7.36 (d, $J = 8.7$ Hz, 1 H), 7.22 (br d, $J = 8.7$ Hz, 2 H), 7.16 (dd, $J = 8.7, 3.1$ Hz, 1 H), 6.88 (br d, $J = 8.7$ Hz, 2 H), 4.51 (d, $J = 11.6$ Hz, 1 H), 4.48 (d, $J = 11.6$ Hz, 1 H), 4.37–4.30 (m, 1 H), 3.81 (s, 3 H), 3.73 (dd, $J = 10.4, 5.2$ Hz, 1 H), 3.69 (dd, $J = 10.3, 4.9$ Hz, 1 H), 3.43 (dd, $J = 10.8, 5.5$ Hz, 1 H), 3.36 (dd, $J = 10.7, 5.4$ Hz, 1 H); HRESIMS calcd for $\text{C}_{16}\text{H}_{18}\text{BrINO}_3$ m/z $[\text{M} + \text{H}]^+$ 479.9490, 477.9509, found 479.9489, 477.9508.

2-Bromo-5-[(2*R*)-1-(2-bromo-4-nitro-1*H*-imidazol-1-yl)-3-[(4-methoxybenzyl)oxy]propan-2-yl]oxy]pyridine (**165**). A mixture of iodide **164** (5.17 g, 10.8 mmol), 2-bromo-4-nitro-1*H*-imidazole (**129**) (2.28 g, 11.9 mmol), and powdered K_2CO_3 (1.79 g, 13.0 mmol) in anhydrous DMF (26 mL) under N_2 was stirred at 88 °C for 122 h. The resulting cooled mixture was added to aqueous NaHCO_3 (100 mL) and extracted with CH_2Cl_2 (6 $\times$ 100 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30 °C), and the residue was chromatographed on silica gel. Elution with 0–30% EtOAc /petroleum ether first gave forerunners, and then further elution with 30–50% EtOAc /petroleum ether gave **165** (4.44 g, 76%) as a pale yellow solid: mp (Et_2O /pentane) 86–88 °C; ^1H NMR (CDCl_3) δ 8.04 (d, $J = 3.1$ Hz, 1 H), 7.83 (s, 1 H), 7.37 (br d, $J = 8.7$ Hz, 1 H), 7.24 (br d, $J = 8.7$ Hz, 2 H), 7.02 (dd, $J = 8.7, 3.2$ Hz, 1 H), 6.92 (br d, $J = 8.7$ Hz, 2 H), 4.63–4.56 (m, 1 H), 4.53 (d, $J = 11.6$ Hz, 1 H), 4.49 (d, $J = 11.6$ Hz, 1 H), 4.46 (dd, $J = 14.8, 3.8$ Hz, 1 H), 4.36 (dd, $J = 14.7, 7.1$ Hz, 1 H), 3.84 (s, 3 H), 3.62 (dd, $J = 10.5, 4.1$ Hz, 1 H), 3.55 (dd, $J = 10.5, 6.1$ Hz, 1 H); HRESIMS calcd for $\text{C}_{19}\text{H}_{18}\text{Br}_2\text{N}_4\text{NaO}_5$ m/z $[\text{M} + \text{Na}]^+$ 566.9500, 564.9517, 562.9536, found 566.9506, 564.9522, 562.9540.

(2*R*)-3-(2-bromo-4-nitro-1*H*-imidazol-1-yl)-2-[(6-bromopyridin-3-yl)oxy]propan-1-ol (**166**). A mixture of PMB ether **165** (4.42 g, 8.15 mmol) and DDQ (1.95 g, 8.59 mmol) in CH_2Cl_2 (175 mL) was stirred at 20 °C for 48 h. Additional DDQ (202 mg, 0.89 mmol) was added, and stirring was continued at 20 °C for 50 h. The resulting mixture was added to saturated aqueous NaHCO_3 (200 mL) and extracted with CH_2Cl_2 (4 $\times$ 150 mL). The extracts were sequentially washed with aqueous NaHCO_3 (150 mL); then the combined extracts were evaporated to dryness under reduced pressure (at 30 °C), and the remaining oil was chromatographed on silica gel. Elution with CH_2Cl_2 first gave forerunners, and then further elution with 3% MeOH/ CH_2Cl_2 gave the crude product mixture (4.09 g) as a pale yellow foam. This material was suspended in 3:1 MeOH/ CH_2Cl_2 (200 mL) and treated with *p*-toluenesulfonic acid monohydrate (0.79 g, 4.15 mmol), stirring at 20 °C for 10 h. Excess NaHCO_3 (0.5 g) was added, and the mixture was concentrated under reduced pressure, then diluted with aqueous NaHCO_3 (100 mL), and extracted with CH_2Cl_2 (5 $\times$ 100 mL). The combined extracts were evaporated to dryness under reduced pressure, and the remaining oil was chromatographed on silica gel. Elution with 0–1% MeOH/ CH_2Cl_2 first gave forerunners, and then further elution with 1–2% MeOH/ CH_2Cl_2 gave **166** (3.32 g, 96%) as a cream solid: mp (MeOH/ CH_2Cl_2 /hexane) 132–133 °C; ^1H NMR $[(\text{CD}_3)_2\text{SO}]$ δ 8.58 (s, 1 H), 8.08 (d, $J = 3.0$ Hz, 1 H), 7.51 (br d, $J = 8.7$ Hz, 1 H), 7.36 (dd, $J = 8.8, 3.2$ Hz, 1 H), 5.25 (br t, $J = 4.7$ Hz, 1 H), 4.85–4.78 (m, 1 H), 4.44 (dd, $J = 14.7, 3.9$ Hz, 1 H), 4.37 (dd, $J = 14.7, 7.8$ Hz, 1 H), 3.72–3.57 (m, 2 H); $[\alpha]_D^{26}$ 13.3 (c 2.032, DMF). Anal. Calcd for $\text{C}_{11}\text{H}_{10}\text{Br}_2\text{N}_4\text{O}_4$: C, 31.31; H, 2.39; N, 13.28. Found: C, 31.55; H, 2.32; N, 13.34.

(6*R*)-6-[(6-bromopyridin-3-yl)oxy]-2-nitro-6,7-dihydro-5*H*-imidazo[2,1-*b*]-[1,3]oxazine (**167**). A solution of alcohol **166** (3.29 g,

7.80 mmol) in anhydrous DMF (50 mL) under N₂ at 0 °C was treated with 60% NaH (419 mg, 10.5 mmol) and then quickly degassed and resealed under N₂. The mixture was stirred at 0 °C for 45 min and then at 20 °C for 160 min, then cooled to –78 °C (CO₂/acetone), the reaction quenched with ice/aqueous NaHCO₃ (20 mL), and the mixture added to brine (200 mL). The resulting mixture was sequentially extracted with CH₂Cl₂ (150 mL), 10% MeOH/CH₂Cl₂ (4 × 150 mL), 20% EtOAc/CH₂Cl₂ (4 × 150 mL), 25% MeOH/CH₂Cl₂ (4 × 150 mL), CH₂Cl₂ (2 × 150 mL), and EtOAc (150 mL), and then the combined extracts were evaporated to dryness under reduced pressure (at 30 °C). The crude residue was triturated in water, filtered and dried, then resuspended in warm 5% MeOH/CH₂Cl₂ (100 mL), cooled, and filtered to give **167** (1.93 g, 73%) as a pale brown solid: mp 244–247 °C; ¹H NMR [(CD₃)₂SO] δ 8.22 (br d, *J* = 3.0 Hz, 1 H), 8.05 (s, 1 H), 7.61 (br d, *J* = 8.6 Hz, 1 H), 7.55 (dd, *J* = 8.8, 3.1 Hz, 1 H), 5.35–5.29 (m, 1 H), 4.69 (dt, *J* = 12.4, 2.1 Hz, 1 H), 4.64 (br d, *J* = 12.2 Hz, 1 H), 4.40 (dd, *J* = 14.0, 3.0 Hz, 1 H), 4.35 (br d, *J* = 14.1 Hz, 1 H); [α]_D²⁵ 21.0 (c 1.000, DMF). Anal. Calcd for C₁₁H₉BrN₄O₄: C, 38.73; H, 2.66; N, 16.42. Found: C, 38.67; H, 2.54; N, 16.40.

The filtrate described above was evaporated to dryness under reduced pressure, and the residue was chromatographed on silica gel. Elution with 0–0.5% MeOH/CH₂Cl₂ first gave forerunners, and then further elution with 0.5–0.67% MeOH/CH₂Cl₂ gave the crude product, which was suspended in warm 10% MeOH/CH₂Cl₂ (15 mL), then diluted with CH₂Cl₂ (20 mL) and hexane (50 mL), and filtered to give additional **167** (233 mg, 9%).

(6*R*)-2-Nitro-6-((6-[4-(trifluoromethoxy)phenyl]pyridin-3-yl)oxy)-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]oxazine (R-168). Reaction of bromide **167** with Pd(dppf)Cl₂ (0.27 equiv) and [4-(trifluoromethoxy)phenyl]boronic acid (1.9 equiv), using procedure I for 210 min, followed by chromatography of the product on silica gel, eluting with 0–0.33% MeOH/CH₂Cl₂ (forerunners) and then with 0.5% MeOH/CH₂Cl₂, gave **R-168** (86%) as a cream solid: mp (MeOH/CH₂Cl₂/hexane) 239–241 °C; ¹H NMR [(CD₃)₂SO] δ 8.46 (d, *J* = 2.9 Hz, 1 H), 8.16 (br d, *J* = 8.9 Hz, 2 H), 8.08 (s, 1 H), 8.01 (d, *J* = 8.7 Hz, 1 H), 7.67 (dd, *J* = 8.8, 3.0 Hz, 1 H), 7.45 (br d, *J* = 8.1 Hz, 2 H), 5.44–5.36 (m, 1 H), 4.73 (dt, *J* = 12.4, 2.1 Hz, 1 H), 4.69 (br d, *J* = 12.0 Hz, 1 H), 4.45 (dd, *J* = 13.9, 3.0 Hz, 1 H), 4.39 (br d, *J* = 14.0 Hz, 1 H); ¹³C NMR [(CD₃)₂SO] δ 151.9, 148.5 (q, *J*_{C–F} = 1.4 Hz), 148.3, 146.9, 142.2, 138.8, 137.4, 127.9 (2 C), 123.9, 121.2 (2 C), 121.1, 120.1 (q, *J*_{C–F} = 256.4 Hz), 118.0, 67.9, 66.0, 46.3; [α]_D²⁵ 6.98 (c 1.003, DMF). Anal. Calcd for C₁₈H₁₃F₃N₄O₅: C, 51.19; H, 3.10; N, 13.27. Found: C, 51.33; H, 2.94; N, 13.27.

Minimum Inhibitory Concentration Assays (MABA and LORA). These assays against *M. tb* were performed according to the reported procedures.^{59,60} Results in Table 1 are the mean of two or three independent determinations (SD data are given in Table S1).

In Vitro Parasite Growth Inhibition Assays. The activity of test compounds against the amastigote stage of the *L. don* parasite was measured at CDRI using a mouse macrophage-based luciferase assay, performed according to the published procedures.²⁶ Replicate assays quantifying the growth inhibitory action of compounds against *L. inf.*, *T. cruzi*, and *T. brucei* and assessing any cytotoxic effects on human lung fibroblasts (MRC-5 cells) were conducted at the University of Antwerp (LMPH), as previously described;⁴⁴ results in Tables 1–4 are the mean of at least two (up to 10) independent determinations (SD data are given in Tables S1–S4). Additional assays using a wider range of VL and CL strains and clinical isolates were performed via comparable methods at LMPH⁴⁴ or LSHTM²⁶ (primary peritoneal mouse macrophages infected with cultured promastigotes were incubated at 37 °C for 24 h prior to the addition of test compounds and then further incubated for either 3 or 5 days for CL or VL assays, respectively).

Solubility Determinations. **Method A.** The solid compound sample was mixed with water or 0.1 M HCl (enough to make a 2 mM solution) in an Eppendorf tube, and the suspension was sonicated for 15 min and then centrifuged at 13000 rpm for 6 min. An aliquot of the clear supernatant was diluted 2-fold with water (or 0.1 M HCl), and then HPLC was performed (as described). The kinetic solubility was

calculated by comparing the peak area obtained with that from a standard solution of the compound in DMSO (after allowing for varying dilution factors and injection volumes).

Method B. The thermodynamic solubility of compound **R-6** at pH 7.4 was measured by Syngene International Ltd. (Plot No. 2 and 3 Biocon Park, Jigani Link Road, Bangalore 560099, India). The dry powder was equilibrated with 0.1 M phosphate buffer (pH 7.4) in a glass vial at 25 °C (water bath), shaking for 24 h. After filtration using a 0.45 μm PVDF membrane filter, the concentration of **R-6** was determined by HPLC (Waters e2695 system, employing a 150 mm × 4.6 mm XBridge 3.5 μm reversed phase C18 column and isocratic elution with 50% CH₃CN in 10 mM ammonium acetate buffer, at 1 mL/min), comparing the peak area obtained with that from a standard solution (0.93 mM) in 1:1:2 EtOH/water/CH₃CN.

Microsomal Stability Assays. Compound **22** was tested by MDS Pharma Services (22011 30th Dr. SE, Bothell, WA 98021-4444), as described previously.⁴⁷ Studies of compounds **24**, **S-51**, **S-77**, **R-77**, **S-81**, **R-81**, **R-84**, **S-89**, **R-89**, **S-91**, **R-91**, **S-92**, **R-92**, **R-94**, **116**, **117**, **S-151**, and **S-155** (Table 5) were run by Advinus Therapeutics Ltd. (21 and 22 Phase II, Peenya Industrial Area, Bangalore 560058, India), using a published procedure⁶¹ in which the compound concentration was 0.5 μM and the incubation time was 30 min. Additional analyses of compounds **R-1**, **R-6**, **R-69**, **R-74**, **R-84**, **R-89**, **R-91**, **R-92**, **R-94**, **R-96**, **R-99**, **R-102**, **R-106**, **R-136**, **R-147**, **R-151**, **R-168**, and **R-169** were performed by WuXi AppTec (Shanghai) Co., Ltd. (288 FuTe ZhongLu, WaiGaoQiao Free Trade Zone, Shanghai 200131, China) via a reported²⁵ method; the compound concentration was 1 μM, and the incubation time was 1 h.

Distribution Coefficient. This was measured by WuXi AppTec (Shanghai) Co., Ltd. The LogD value of **R-6** was found by assessing its distribution between 100 mM phosphate buffer (pH 7.4) and octanol at room temperature (final matrix contained 1% DMSO), using the shake-flask method and LC–MS/MS analysis.

Permeability Assay. The assay was performed by WuXi AppTec (Shanghai) Co., Ltd. MDCK-MDR1 cells were seeded onto polyethylene membranes in 96-well plates at a density of 2 × 10⁵ cells/cm², giving confluent cell monolayer formation over 4–7 days. A solution of **R-6** (2 μM in 0.4% DMSO/HBSS buffer) was applied to the apical or basolateral side of the cell monolayer. Permeation of the compound in the A to B direction or B to A direction was assessed in triplicate over a 150 min incubation at 37 °C and 5% CO₂ (95% humidity). In addition, the efflux ratio of **R-6** was also determined. Test and reference compounds were quantified by LC–MS/MS analysis based on the peak area ratio of the analyte/internal standard.

Plasma Protein Binding Assays. The studies of **4** and **R-6** were performed by WuXi AppTec (Shanghai) Co., Ltd., using equilibrium dialysis across a semipermeable membrane. Briefly, 2 μM compound solutions in plasma were dialyzed against 100 mM phosphate-buffered saline (pH 7.4) on a rotating plate (150 rpm) incubated at 37 °C for 4 or 6 h. Following precipitation of protein with CH₃CN, the amount of compound present in each compartment was quantified by LC–MS/MS; values are the mean of triplicate determinations.

Ames Test. Compounds **R-6** and **R-136** (at doses of 1.5, 4, 10, 25, 64, 160, 400, and 1000 μg/well) were evaluated in triplicate in the Mini-Ames reverse mutation screen conducted by WuXi AppTec (Suzhou) Co., Ltd. (1318 Wuzhong Ave., Wuzhong District, Suzhou 215104, China). Two strains of *Salmonella typhimurium* (TA98 and TA100) were employed, in the presence and absence of metabolic activation (rat liver S9). Positive controls (2-aminoanthracene, 2-nitrofluorene, and sodium azide) and a negative (DMSO solvent) control were included.

hERG Assay. The effects of compounds **R-6**, **R-84**, **R-89**, and **R-136** on cloned hERG potassium channels expressed in Chinese hamster ovary cells were assessed by WuXi AppTec (Shanghai) Co., Ltd., using the automated patch clamp method. Six concentrations (0.12, 0.37, 1.11, 3.33, 10, and 30 μM) were tested (at room temperature), and at least three replicates were obtained for each.

CYP3A4 Inhibition Assay. This work was performed by WuXi AppTec (Shanghai) Co., Ltd. Compound **R-6** (at concentrations of 1 and 10 μM) was incubated with NADPH-fortified pooled HLM (0.2

mg/mL) and testosterone (50 μ M) in phosphate buffer (100 mM) at 37 °C for 10 min. Following quenching with CH₃CN, samples were analyzed for the formation of 6 β -hydroxytestosterone by LC–MS/MS, and the percentage inhibition was determined (ketoconazole was the positive control, and tolbutamide was used as an internal standard).

In Vivo Experiments. All animal experiments were performed according to institutional ethical guidelines for animal care. Mouse model studies (LSHTM) were conducted under license (PPL X20014A54), according to UK Home Office regulations, Animals (Scientific Procedures) Act 1986, and European Directive 2010/63/EU, and hamster studies (LMPH) were approved by the ethical committee of the University of Antwerp (UA-ECD 2010–17).

Acute VL Infection Assay (mouse model, LSHTM). Test compounds were orally administered once per day for 5 days consecutively to groups of five female BALB/c mice infected with 2×10^7 *L. don* amastigotes, with treatment commencing 1 week postinfection, as described previously.²⁶ Miltefosine and AmBisome were positive controls, and parasite burdens were determined from impression smears of liver sections. Efficacy was expressed as the mean percentage reduction in parasite load for treated mice in comparison to untreated (vehicle-only) controls (SD data are provided in Table S5). Derived ED₅₀ values (with 95% confidence limits, as specified in Table S5) were obtained from GraphPad Prism 6 software, using a four-parametric sigmoidal variable slope dose–response curve.

Chronic VL Infection Assay (hamster model, LMPH). Golden hamsters (weighing 75–80 g) were infected with 2×10^7 *L. inf* amastigotes, and 21 days postinfection, treatment groups of six animals each were treated orally twice per day with test compounds (formulated in PEG-400) for 5 days consecutively. Parasite burdens in three target organs (liver, spleen, and bone marrow) were determined by microscopic evaluation of impression smears (stained with Giemsa), and efficacy was expressed as the mean percentage parasite load reduction for treated hamsters in comparison to untreated (vehicle-only) controls (SD data are given in Table S6). Miltefosine was included as a reference drug in all experiments.

Mouse Pharmacokinetics. Testing of compounds 24, 116, and 117 was executed by Advinus Therapeutics Ltd., according to a published protocol.⁶¹ Briefly, compounds were administered to groups of male Swiss albino mice; intravenous dosing (at 1 mg/kg) employed a solution vehicle comprising 20% NMP and 40% PEG-400 in 100 mM citrate buffer (pH 3), while oral dosing (at 25 mg/kg) was as a suspension in 0.5% carboxymethylcellulose (CMC) and 0.08% Tween 80 in water. Samples derived from plasma (at 0.083 for iv only, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 24, and 48 h) were centrifuged prior to analysis by LC–MS/MS, and the PK parameters were determined using Phoenix WinNonlin software (version 5.2). The remaining compounds (R-6, R-84, R-89, and R-136) were assessed by WuXi AppTec (Shanghai) Co., Ltd.; in this case, oral dosing of female BALB/c mice occurred at 40–50 mg/kg in PEG-400 (sampling at 0.25, 1, 2, 4, 8, and 24 h), and the PK data were obtained using WinNonlin software (version 6.2) following similar LC–MS/MS analysis.

Rat and Hamster Pharmacokinetics. All studies were conducted in fasted animals (either male Sprague-Dawley rats or female golden Syrian hamsters) by WuXi AppTec (Shanghai) Co., Ltd. Intravenous dosing (at 1 mg/kg for rats and 2 mg/kg for hamsters) utilized a solution formulation of 20% NMP and 40% PEG-400 in citrate buffer (pH 3). In rats, oral dosing (at 40–50 mg/kg) was as a suspension in 0.08% Tween 80 and 0.5% CMC in water, whereas PEG-400 was the vehicle employed for oral dosing in hamsters (at 40–50 mg/kg). Plasma samples (at 0.083 for iv only, 0.25, 0.5, 1, 2, 4, 8, and 24 h) were analyzed by LC–MS/MS, and the PK parameters were calculated using Phoenix WinNonlin software (version 6.3).

■ ASSOCIATED CONTENT

■ Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.7b01581.

Additional biological assay data, synthetic schemes, graphs of PK data, experimental procedures and characterizations for compounds, combustion analytical data, and representative NMR spectra (PDF)
Molecular formula strings spreadsheet (CSV)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: am.thompson@auckland.ac.nz. Phone: (+649) 923-6145. Fax: (+649) 373-7502.

ORCID

Andrew M. Thompson: 0000-0003-2593-8559

William A. Denny: 0000-0001-7997-1843

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The authors thank the Global Alliance for TB Drug Development (TB Alliance) and the Drugs for Neglected Diseases initiative (DNDi) for financial support through collaborative research agreements. For this project, the TB Alliance acknowledges grant funding from the Bill & Melinda Gates Foundation (OPP40827), while DNDi received financial support from the following donors: Department for International Development (DFID), of the U.K.; Federal Ministry of Education and Research (BMBF), through KfW Germany; Directorate-General for International Cooperation (DGIS), of The Netherlands; Bill & Melinda Gates Foundation (grant OPP48262); and Médecins Sans Frontières (MSF) International. The donors had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors also thank Drs. Jakir Pinjari and Rao Mukkavilli (Advinus Therapeutics Ltd., Bangalore, India) for some PK data, Sisira Kumara (ACSRC) for the kinetic solubility measurements, and Dr. Beatrice Bonnet (DNDi) for providing some new data and comments on the large scale synthesis of the lead.

■ ABBREVIATIONS USED

VL, visceral leishmaniasis; TPP, target product profile; *M. tb*, *M. tuberculosis*; TB, tuberculosis; *L. inf*, *L. infantum*; *L. don*, *L. donovani*; HLM, human liver microsomes; PK, pharmacokinetic; DMPK, drug metabolism and pharmacokinetic; MLM, mouse liver microsomes; PD, pharmacodynamic; HREIMS, high-resolution electron impact mass spectrometry; HRCIMS, high-resolution chemical ionization mass spectrometry; HRFABMS, high-resolution fast atom bombardment mass spectrometry; HRESIMS, high-resolution electrospray ionization mass spectrometry; APCI MS, atmospheric-pressure chemical ionization mass spectrometry; DIPEA, *N,N*-diisopropylethylamine; NMM, *N*-methylemorpholine; CMC, carboxymethylcellulose; MIL, miltefosine; SD, standard deviation

■ REFERENCES

- (1) Leishmaniasis. World Health Organization: Geneva, 2017. <http://www.who.int/mediacentre/factsheets/fs375/en/> (accessed June 22, 2017).
- (2) Karimi, A.; Alborzi, A.; Amanati, A. Visceral leishmaniasis: An update and literature review. *Archives of Pediatric Infectious Diseases* 2016, 4 (3), e31612.
- (3) den Boer, M.; Argaw, D.; Jannin, J.; Alvar, J. Leishmaniasis impact and treatment access. *Clin. Microbiol. Infect.* 2011, 17, 1471–1477.

- (4) Al-Salem, W.; Herricks, J. R.; Hotez, P. J. A review of visceral leishmaniasis during the conflict in South Sudan and the consequences for East African countries. *Parasites Vectors* **2016**, *9*, 460.
- (5) Sunyoto, T.; Potet, J.; Boelaert, M. Visceral leishmaniasis in Somalia: A review of epidemiology and access to care. *PLoS Neglected Trop. Dis.* **2017**, *11* (3), e0005231.
- (6) Kimutai, R.; Musa, A. M.; Njoroge, S.; Omollo, R.; Alves, F.; Hailu, A.; Khalil, E. A. G.; Diro, E.; Soipei, P.; Musa, B.; Salman, K.; Ritmeijer, K.; Chappuis, F.; Rashid, J.; Mohammed, R.; Jameneh, A.; Makonnen, E.; Olobo, J.; Okello, L.; Sagaki, P.; Strub, N.; Ellis, S.; Alvar, J.; Balasegaram, M.; Alirol, E.; Wasunna, M. Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in Eastern Africa: Results from a pharmacovigilance programme. *Clin. Drug Invest.* **2017**, *37*, 259–272.
- (7) Wasunna, M.; Njenga, S.; Balasegaram, M.; Alexander, N.; Omollo, R.; Edwards, T.; Dorlo, T. P. C.; Musa, B.; Ali, M. H. S.; Elamin, M. Y.; Kirigi, G.; Juma, R.; Kip, A. E.; Schoone, G. J.; Hailu, A.; Olobo, J.; Ellis, S.; Kimutai, R.; Wells, S.; Khalil, E. A. G.; Strub, Wourgaft, N.; Alves, F.; Musa, A. Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: Phase II randomized trial. *PLoS Neglected Trop. Dis.* **2016**, *10* (9), e0004880.
- (8) Fexinidazole/Miltefosine Combination (VL). DNDi, 2016. <https://www.dndi.org/diseases-projects/portfolio/completed-projects/fexinidazole-vl/> (accessed June 22, 2017).
- (9) Singh, N.; Mishra, B. B.; Bajpai, S.; Singh, R. K.; Tiwari, V. K. Natural product based leads to fight against leishmaniasis. *Bioorg. Med. Chem.* **2014**, *22*, 18–45.
- (10) Target Product Profile for Visceral Leishmaniasis. DNDi, 2017. <https://www.dndi.org/diseases-projects/leishmaniasis/tpp-vl/> (accessed December 7, 2017).
- (11) Nagle, A. S.; Khare, S.; Kumar, A. B.; Supek, F.; Buchynskyy, A.; Mathison, C. J. N.; Chennamaneni, N. K.; Pendem, N.; Buckner, F. S.; Gelb, M. H.; Molteni, V. Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis. *Chem. Rev.* **2014**, *114*, 11305–11347.
- (12) Field, M. C.; Horn, D.; Fairlamb, A. H.; Ferguson, M. A. J.; Gray, D. W.; Read, K. D.; De Rycker, M.; Torrie, L. S.; Wyatt, P. G.; Wyllie, S.; Gilbert, I. H. Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. *Nat. Rev. Microbiol.* **2017**, *15*, 217–231.
- (13) Don, R.; Ioset, J.-R. Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections. *Parasitology* **2014**, *141*, 140–146.
- (14) Liévin-Le Moal, V.; Loiseau, P. M. *Leishmania* hijacking of the macrophage intracellular compartments. *FEBS J.* **2016**, *283*, 598–607.
- (15) Naderer, T.; Vince, J. E.; McConville, M. J. Surface determinants of *Leishmania* parasites and their role in infectivity in the mammalian host. *Curr. Mol. Med.* **2004**, *4*, 649–665.
- (16) Katsuno, K.; Burrows, J. N.; Duncan, K.; Hooft van Huijsduijnen, R.; Kaneko, T.; Kita, K.; Mowbray, C. E.; Schmatz, D.; Warner, P.; Slingsby, B. T. Hit and lead criteria in drug discovery for infectious diseases of the developing world. *Nat. Rev. Drug Discovery* **2015**, *14*, 751–758.
- (17) Burrows, J. N.; Elliott, R. L.; Kaneko, T.; Mowbray, C. E.; Waterson, D. The role of modern drug discovery in the fight against neglected and tropical diseases. *MedChemComm* **2014**, *5*, 688–700.
- (18) Mowbray, C. E.; Braillard, S.; Speed, W.; Glossop, P. A.; Whitlock, G. A.; Gibson, K. R.; Mills, J. E. J.; Brown, A. D.; Gardner, J. M. F.; Cao, Y.; Hua, W.; Morgans, G. L.; Feijens, P.-B.; Matheeußen, A.; Maes, L. J. Novel amino-pyrazole ureas with potent in vitro and in vivo antileishmanial activity. *J. Med. Chem.* **2015**, *58*, 9615–9624.
- (19) Khare, S.; Nagle, A. S.; Biggart, A.; Lai, Y. H.; Liang, F.; Davis, L. C.; Barnes, S. W.; Mathison, C. J. N.; Myburgh, E.; Gao, M.-Y.; Gillespie, J. R.; Liu, X.; Tan, J. L.; Stinson, M.; Rivera, I. C.; Ballard, J.; Yeh, V.; Groessl, T.; Federe, G.; Koh, H. X. Y.; Venable, J. D.; Bursulaya, B.; Shapiro, M.; Mishra, P. K.; Spraggon, G.; Brock, A.; Mottram, J. C.; Buckner, F. S.; Rao, S. P. S.; Wen, B. G.; Walker, J. R.; Tuntland, T.; Molteni, V.; Glynn, R. J.; Supek, F. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. *Nature* **2016**, *537*, 229–233.
- (20) Mukherjee, T.; Boshoff, H. Nitroimidazoles for the treatment of TB: past, present and future. *Future Med. Chem.* **2011**, *3*, 1427–1454.
- (21) Diacon, A. H.; Dawson, R.; du Bois, J.; Narunsky, K.; Venter, A.; Donald, P. R.; van Niekerk, C.; Erond, N.; Ginsberg, A. M.; Becker, P.; Spigelman, M. K. Phase II dose-ranging trial of the early bactericidal activity of PA-824. *Antimicrob. Agents Chemother.* **2012**, *56*, 3027–3031.
- (22) Murray, S.; Mendel, C.; Spigelman, M. TB Alliance regimen development for multidrug-resistant tuberculosis. *International Journal of Tuberculosis and Lung Disease* **2016**, *20* (Suppl. 1), S38–S41.
- (23) Upton, A. M.; Cho, S.; Yang, T. J.; Kim, Y.; Wang, Y.; Lu, Y.; Wang, B.; Xu, J.; Mdululi, K.; Ma, Z.; Franzblau, S. G. *In vitro* and *in vivo* activities of the nitroimidazole TBA-354 against *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **2015**, *59*, 136–144.
- (24) Thompson, A. M.; O'Connor, P. D.; Marshall, A. J.; Yardley, V.; Maes, L.; Gupta, S.; Launay, D.; Braillard, S.; Chatelain, E.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Cooper, C. B.; Denny, W. A. 7-Substituted 2-nitro-5,6-dihydroimidazo[2,1-*b*][1,3]oxazines: novel antitubercular agents lead to a new preclinical candidate for visceral leishmaniasis. *J. Med. Chem.* **2017**, *60*, 4212–4233.
- (25) Thompson, A. M.; O'Connor, P. D.; Blaser, A.; Yardley, V.; Maes, L.; Gupta, S.; Launay, D.; Martin, D.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Denny, W. A. Repositioning antitubercular 6-nitro-2,3-dihydroimidazo[2,1-*b*][1,3]oxazines for neglected tropical diseases: structure-activity studies on a preclinical candidate for visceral leishmaniasis. *J. Med. Chem.* **2016**, *59*, 2530–2550.
- (26) Gupta, S.; Yardley, V.; Vishwakarma, P.; Shivhare, R.; Sharma, B.; Launay, D.; Martin, D.; Puri, S. K. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis. *J. Antimicrob. Chemother.* **2015**, *70*, 518–527.
- (27) Wyllie, S.; Roberts, A. J.; Norval, S.; Patterson, S.; Foth, B. J.; Berriman, M.; Read, K. D.; Fairlamb, A. H. Activation of bicyclic nitrodrugs by a novel nitroreductase (NTR2) in *Leishmania*. *PLoS Pathog.* **2016**, *12* (11), e1005971.
- (28) Patterson, S.; Wyllie, S.; Norval, S.; Stojanovski, L.; Simeons, F. R. C.; Auer, J. L.; Osuna-Cabello, M.; Read, K. D.; Fairlamb, A. H. The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. *eLife* **2016**, *5*, e09744.
- (29) Thompson, A. M.; Denny, W. A.; Blaser, A.; Ma, Z. Nitroimidazooxazine and Nitroimidazooxazole Analogues and Their Uses. Patent WO 2011/014776 A1, 2011, and U.S. Patent 8293734 B2, 2012.
- (30) Thompson, A. M.; Blaser, A.; Palmer, B. D.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Denny, W. A. Biaryl-methoxy 2-nitroimidazooxazine antituberculosis agents: Effects of proximal ring substitution and linker reversal on metabolism and efficacy. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 3804–3809.
- (31) Li, X.; Manjunatha, U. H.; Goodwin, M. B.; Knox, J. E.; Lipinski, C. A.; Keller, T. H.; Barry, C. E.; Dowd, C. S. Synthesis and antitubercular activity of 7-(*R*)- and 7-(*S*)-methyl-2-nitro-6-(*S*)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5*H*-imidazo[2,1-*b*][1,3]-oxazines, analogues of PA-824. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 2256–2262.
- (32) Baker, W. R.; Shaopei, C.; Keeler, E. L. Nitro-[2,1-*b*]imidazopyran Compounds and Antibacterial Uses Thereof. U.S. Patent 6087358, 2000.
- (33) Hirata, M.; Fujimoto, R.; Mikami, M. Preparation of 2-Methylglycidyl Ethers from 3-Halogeno-2-methyl-1,2-propanediols or 2-Methylepialohydrins. Patent JP 2007297330, 2007.
- (34) Elbert, B. L.; Lim, D. S. W.; Gudmundsson, H. G.; O'Hanlon, J. A.; Anderson, E. A. Synthesis of cyclic alkenylsiloxanes by semi-hydrogenation: a stereospecific route to (*Z*)-alkenyl polyenes. *Chem. - Eur. J.* **2014**, *20*, 8594–8598.
- (35) Ginsberg, A. M.; Laurenzi, M. W.; Rouse, D. J.; Whitney, K. D.; Spigelman, M. K. Safety, tolerability, and pharmacokinetics of PA-824

in healthy subjects. *Antimicrob. Agents Chemother.* **2009**, *53*, 3720–3725.

(36) Thompson, A. M.; Marshall, A. J.; Maes, L.; Yarlett, N.; Bacchi, C. J.; Gaukel, E.; Wring, S. A.; Launay, D.; Braillard, S.; Chatelain, E.; Mowbray, C. E.; Denny, W. A. Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides. *Bioorg. Med. Chem. Lett.* **2018**, *28*, 207–213.

(37) Gurumurthy, M.; Mukherjee, T.; Dowd, C. S.; Singh, R.; Niyomrattanakit, P.; Tay, J. A.; Nayyar, A.; Lee, Y. S.; Cherian, J.; Boshoff, H. I.; Dick, T.; Barry, C. E., III; Manjunatha, U. H. Substrate specificity of the deazaflavin-dependent nitroreductase from *Mycobacterium tuberculosis* responsible for the bio-reductive activation of bicyclic nitroimidazoles. *FEBS J.* **2012**, *279*, 113–125.

(38) Patterson, S.; Wyllie, S.; Stojanovski, L.; Perry, M. R.; Simeons, F. R. C.; Norval, S.; Osuna-Cabello, M.; De Rycker, M.; Read, K. D.; Fairlamb, A. H. The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral leishmaniasis. *Antimicrob. Agents Chemother.* **2013**, *57*, 4699–4706.

(39) Kmentova, I.; Sutherland, H. S.; Palmer, B. D.; Blaser, A.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Denny, W. A.; Thompson, A. M. Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-[[4-(trifluoromethoxy)benzyl]oxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). *J. Med. Chem.* **2010**, *53*, 8421–8439.

(40) Thompson, A. M.; Blaser, A.; Anderson, R. F.; Shinde, S. S.; Franzblau, S. G.; Ma, Z.; Denny, W. A.; Palmer, B. D. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bio-reductive drug (6S)-2-nitro-6-[[4-(trifluoromethoxy)benzyl]oxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). *J. Med. Chem.* **2009**, *52*, 637–645.

(41) Bom, D.; Curran, D. P.; Kruszewski, S.; Zimmer, S. G.; Thompson Strode, J.; Kohlhaagen, G.; Du, W.; Chavan, A. J.; Fraley, K. A.; Bingcan, A. L.; Latus, L. J.; Pommier, Y.; Burke, T. G. The novel silatcan 7-tert-butylidimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. *J. Med. Chem.* **2000**, *43*, 3970–3980.

(42) Thompson, A. M.; Sutherland, H. S.; Palmer, B. D.; Kmentova, I.; Blaser, A.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Denny, W. A. Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-[[4-(trifluoromethoxy)benzyl]oxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). *J. Med. Chem.* **2011**, *54*, 6563–6585.

(43) Alberati-Giani, D.; Jolidon, S.; Narquizian, R.; Nettekoven, M. H.; Norcross, R. D.; Pinard, E.; Stalder, H. Preparation of 1-(2-Aminobenzoyl)-piperazine Derivatives as Glycine Transporter 1 (GlyT-1) Inhibitors for Treating Psychoses. Patent WO 2005023260 A1, 2005.

(44) Kaiser, M.; Maes, L.; Tadoori, L. P.; Spangenberg, T.; Ioset, J.-R. Repurposing of the open access malaria box for kinetoplastid diseases identifies novel active scaffolds against trypanosomatids. *J. Biomol. Screening* **2015**, *20*, 634–645.

(45) Siqueira-Neto, J. L.; Song, O.-R.; Oh, H.; Sohn, J.-H.; Yang, G.; Nam, J.; Jang, J.; Cecchetto, J.; Lee, C. B.; Moon, S.; Genovesio, A.; Chatelain, E.; Christophe, T.; Freitas-Junior, L. H. Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds. *PLoS Neglected Trop. Dis.* **2010**, *4* (5), e675.

(46) Palmer, B. D.; Sutherland, H. S.; Blaser, A.; Kmentova, I.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Denny, W. A.; Thompson, A. M. Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-[[4-(trifluoromethoxy)benzyl]oxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). *J. Med. Chem.* **2015**, *58*, 3036–3059.

(47) Palmer, B. D.; Thompson, A. M.; Sutherland, H. S.; Blaser, A.; Kmentova, I.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Denny, W. A. Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-[[4-(trifluoromethoxy)benzyl]oxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). *J. Med. Chem.* **2010**, *53*, 282–294.

(48) Blaser, A.; Palmer, B. D.; Sutherland, H. S.; Kmentova, I.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Thompson, A. M.; Denny, W. A. Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-[[4-(trifluoromethoxy)benzyl]oxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). *J. Med. Chem.* **2012**, *55*, 312–326.

(49) Sutherland, H. S.; Blaser, A.; Kmentova, I.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Palmer, B. D.; Denny, W. A.; Thompson, A. M. Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chains. *J. Med. Chem.* **2010**, *53*, 855–866.

(50) Kataoka, M.; Fukahori, M.; Ikemura, A.; Kubota, A.; Higashino, H.; Sakuma, S.; Yamashita, S. Effects of gastric pH on oral drug absorption: In vitro assessment using a dissolution/permeation system reflecting the gastric dissolution process. *Eur. J. Pharm. Biopharm.* **2016**, *101*, 103–111.

(51) Rouault, E.; Lecoeur, H.; Meriem, A. B.; Minoprio, P.; Goyard, S.; Lang, T. Imaging visceral leishmaniasis in real time with golden hamster model: Monitoring the parasite burden and hamster transcripts to further characterize the immunological responses of the host. *Parasitol. Int.* **2017**, *66*, 933–939.

(52) Yao, X.; Anderson, D. L.; Ross, S. A.; Lang, D. G.; Desai, B. Z.; Cooper, D. C.; Wheelan, P.; McIntyre, M. S.; Bergquist, M. L.; MacKenzie, K. I.; Becherer, J. D.; Hashim, M. A. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anesthetized guinea-pig model. *Br. J. Pharmacol.* **2008**, *154*, 1446–1456.

(53) Nwaka, S.; Ramirez, B.; Brun, R.; Maes, L.; Douglas, F.; Ridley, R. Advancing drug innovation for neglected diseases - criteria for lead progression. *PLoS Neglected Trop. Dis.* **2009**, *3* (8), e440.

(54) Freitas-Junior, L. H.; Chatelain, E.; Kim, H. A.; Siqueira-Neto, J. L. Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? *Int. J. Parasitol.: Drugs Drug Resist.* **2012**, *2*, 11–19.

(55) Tweats, D.; Bourdin Trunz, B.; Torreele, E. Genotoxicity profile of fexinidazole - a drug candidate in clinical development for human African trypanosomiasis (sleeping sickness). *Mutagenesis* **2012**, *27*, 523–532.

(56) Pilkington, L. I.; Barker, D. Total synthesis of (–)-isoamericanin A and (+)-isoamericanol A. *Eur. J. Org. Chem.* **2014**, *2014*, 1037–1046.

(57) Andresen, T. L.; Jensen, S. S.; Madsen, R.; Jørgensen, K. Synthesis and biological activity of anticancer ether lipids that are specifically released by phospholipase A₂ in tumor tissue. *J. Med. Chem.* **2005**, *48*, 7305–7314.

(58) Patterson, S.; Wyllie, S. Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects. *Trends Parasitol.* **2014**, *30*, 289–298.

(59) Falzari, K.; Zhu, Z.; Pan, D.; Liu, H.; Hongmanee, P.; Franzblau, S. G. In vitro and in vivo activities of macrolide derivatives against *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **2005**, *49*, 1447–1454.

(60) Cho, S. H.; Warit, S.; Wan, B.; Hwang, C. H.; Pauli, G. F.; Franzblau, S. G. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **2007**, *51*, 1380–1385.

(61) Mukkavilli, R.; Pinjari, J.; Patel, B.; Sengottavelan, S.; Mondal, S.; Gadekar, A.; Verma, M.; Patel, J.; Pothuri, L.; Chandrashekar, G.; Koiram, P.; Harisudhan, T.; Moinuddin, A.; Launay, D.; Vachharajani, N.; Ramanathan, V.; Martin, D. In vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis. *Eur. J. Pharm. Sci.* **2014**, *65*, 147–155.

(62) Hendrickx, S.; Van den Kerkhof, M.; Mabilie, D.; Cos, P.; Delputte, P.; Maes, L.; Caljon, G. Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in *Leishmania infantum*. *PLoS Neglected Trop. Dis.* **2017**, *11* (5), e0005620.